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Reactive oxygen species (ROS), including hydroxyl radical (OH), hydrogen 
peroxide (H2O2), superoxide anion radical {O'i), singlet oxygen ('O2) and peroxyl radicals 
are generated during various metabolic and biochemical reactions. They are well known 
to be cytotoxic and may be implicated in the etiology of a number of human diseases. 
Among these radicals, hydroxyl radical is an extremely reactive oxidizing radical 
that reacts with cell biomolecules. It is also believed to be responsible for damage to 
chromatin and nucleosomes. Superoxide anion radical is considered to be a highly toxic 
entity in many biological systems. It is formed in normal metabolism as well as through 
the action of many drugs, poisons and radiation. It is involved in radiation damage, DNA 
damage, phagocytosis, ageing, cancer etc. Superoxide radical interacts with hydrogen 
peroxide to generate singlet oxygen which is also generated predominantly in 
photosensitization reactions. Singlet oxygen has been implicated in several biological 
processes that may lead to genetic damage. It is a chemically aggressive oxygen species, 
capable of attacking cellular components critical for cell survival. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of 
unknown etiology characterized by various immunologic disorders, including production 
of autoantibodies, formation of immune complexes, decreased serum complement levels, 
and lymphocytopenia. The complex and non-organ specific nature of SLE has made it 
difficult for researchers to unravel the genetic defects and pathogenic mechanisms 
underlying this disease. One of the hallmarks of this disease, both in humans and mice, is 
the loss of tolerance to nuclear antigens. The dominant presence of antibodies against the 
exposed conformational epitopes on chromatin strongly suggests that the pathogenic 
immune response in lupus is driven by chromatin. The demonstration of T cells specific 
for chromatin components that can drive the antinuclear antibody producing B cells in 
both murine and human lupus further illustrates how loss of B cell and T cell tolerance to 
chromatin constitutes a central feature of lupus. Although antibodies that react with B 
conformations of DNA are foimd in sera of patients with SLE, B-DNA per se is a poor 
immunogen. On the other hand, various other conformations like right handed A-form 
and left handed Z-form are immunogenic. Also, DNA modified with ROS, certain 
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chemicals, in conjunction with the female sex hormone estradiol have been found to 
result in the production of autoantibodies. It has been reported that ROS modification of 
dsDNA results in an increased binding of anti-DNA antibodies from SLE sera. 
Continuous endogenous damage to cellular DNA by free radicals and 
accumulation of such damage has been suggested to significantly contribute to 
carcinogenesis in humans. Because of their ability to damage DNA, free radicals are 
thought to be involved in all stages of carcinogenesis. Various carcinogens exert their 
effect by generating ROS during their metabolism. 
In the present study, chromatin was isolated from goat liver and modified by 
superoxide anion radicals and singlet oxygen generated by illumination of riboflavin on 
exposure to UV light and hydroxyl radical generated by UV irradiation of hydrogen 
peroxide. The damage to chromatin by these free radicals includes strand breaks and 
DNA base modifications. The modifications incurred in DNA of chromatin were 
analyzed by UV and fluorescence spectroscopic techniques. '02-02"-chromatin showed 
hyperchromicity at 260 nm as compared to native chromatin, reflecting the presence of 
single stranded regions and alterations in the structure of chromatin. 'OH-chromatin 
showed hypochromicity at 260 nm reflecting the damage of chromophoric groups and 
structural alterations. The Tm of '02-02"-chromatin was found to be TS'C whereas native 
chromatin showed a Tm of 83T. 'OH-chromatin showed a Tm of 74"C. A net decrease of 
5°C in the Tm value of '02-02"-chromatin and a net decrease of 9°C in the Tm value of 
'OH-chromatin indicates alterations in the structure and single strand breaks in the DNA 
of chromatin. Nuclease SI sensitivity assay further substantiated the formation of single 
strand breaks. 
Native chromatin, *02-02'-chromatin and 'OH-chromatin were used to induce 
antibodies in rabbits and were found to be immunogenic inducing high titre antibodies. 
The modifled chromatin was highly unmunogenic as compared to native chromatin. The 
antigenic specificity of the induced antibodies was studied by competition ELISA. The 
immunogen showed a high degree of stv'Jficity for the induced antibodies. Protein A-
Sepharose purified immune IgG showed higher specificity as compared to serum. 
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Increased immunogenicity of oxygen free radical modified chromatin could be co-related 
to a feature of SLE, wherein chromatin or oligonucleosomes/nucleosomes become 
immunogenic as a result of damage due to ROS against which antibodies are elicited. 
Twenty four SLE sera from patients having high titre anti-DNA autoantibodies 
were studied for their binding to native chromatin, 'Oi-Oi'-chromatin and *0H-
chromatin. The binding specificity of SLE autoantibodies was analyzed by inhibition 
ELISA. In direct binding assay, SLE autoantibodies bound 'Oi-Or-chromatin and 'OH-
chromatin in preference to native chromatin. This preference was confirmed by inhibition 
ELISA. The binding specificity of native and modified chromatin with SLE 
autoantibodies was reiterated by gel retardation assay. 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and modified chromatin. For the study, sera of various patients with oral cancer, 
cancer of head and neck, urinary bladder, gall bladder, prostrate, lung, breast, CML and 
Hodgkin's lymphoma were screened. Direct binding ELISA results showed greater 
recognition to '02-02~-chromatin and 'OH-chromatin over native chromatin. The binding 
specificity of antibodies in these sera to native and modified chromatin was assessed by 
competitive binding assay. The higher binding to modified chromatin over native 
chromatin by most of the serum samples suggests the involvement of oxygen fi«e radical 
modified chromatin in the production of autoantibodies in cancer patients. 
In conclusion, superoxide anion radical, singlet oxygen and hydroxyl radical cause 
damage to chromatin and render it highly immunogenic. Results indicate possible role of 
modified chromatin in the induction of anti-DNA response in SLE. Higher, recognition of 
oxygen free radical modified chromatin by antibodies in sera of patients with cancer 
and/or SLE suggests free radical induced chromatin damage in patients. It is postulated 
that '02-02'^modified chromatin and 'OH-modified chromatin may play a major role in 
the production of SLE anti-DNA autoantibodies and circulating antibodies in cancer. 
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Reactive oxygen species (ROS), including hydroxy! radical (OH), hydrogen 
peroxide (H2O2), superoxide anion radical (OD, singlet oxygen ('O2) and peroxyl 
radicals are generated during various metabolic and biochemical reactions. They are well 
known to be cytotoxic and may be implicated in the etiology of a number of human 
diseases. 
Among these radicals, hydroxyl radical is an extremely reactive oxidizing radical 
that reacts with cell biomolecules. It is also believed to be responsible for damage to 
chromatin and nucleosomes. Superoxide anion radical is considered to be a highly toxic 
entity in many biological systems. It is formed in normal metabolism as well as through 
the action of many drugs, poisons and radiation. It is involved in radiation damage, DNA 
damage, phagocytosis, ageing, cancer etc. Superoxide radical interacts with hydrogen 
peroxide to generate singlet oxygen which is also generated predominantly in 
photosensitization reactions. Singlet oxygen has been implicated in several biological 
processes that may lead to genetic damage. It is a chemically aggressive oxygen species, 
capable of attacking cellular components critical for cell survival. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of 
unknown etiology characterized by various immunologic disorders, including production 
of autoantibodies, formation of immune complexes, decreased serum complement levels, 
and lymphocytopenia. The complex and non-organ specific nature of SLE has made it 
difficult for researchers to unravel the genetic defects and pathogenic mechanisms 
imderlying this disease. One of the hallmarks of this disease, both in humans and mice, is 
the loss of tolerance to nuclear antigens. The dominant presence of antibodies against the 
exposed conformational epitopes on chromatin strongly suggests that the pathogenic 
mmiune response in lupus is driven by chromatin. The demonstration of T cells specific 
for chromatin components that can drive the antinuclear antibody producing B cells in 
both murine and human lupus further illustrates how loss of B cell and T cell tolerance to 
chromatin constitutes a central feature of lupus. Although antibodies that react with 8 
conformations of DNA are found in sera of patients with SLE, B-DNA per se is a poor 
immunogen. On the other hand, various other conformations like right handed A-form 
and left handed Z-form are immunogenic. Also, DNA modified with ROS, certain 
chemicals, in conjimction with the female sex hormone estradiol have been foimd to 
resuh in the production of autoantibodies. It has been reported that ROS modification of 
dsDNA results in an increased binding of anti-DNA antibodies from SLE sera. 
Continuous endogenous damage to cellular DNA by free radicals and 
accumulation of such damage has been suggested to significantly contribute to 
carcinogenesis in humans. Because of their ability to damage DNA, free radicals are 
thought to be involved in all stages of carcinogenesis. Various carcinogens exert their 
effect by generating ROS during their metabolism. 
In the present study, chromatin was isolated from goat liver and modified by 
superoxide anion radicals and singlet oxygen generated by illumination of riboflavin on 
exposure to UV light and hydroxyl radical generated by UV irradiation of hydrogen 
peroxide. The damage to chromatin by these free radicals includes strand breaks and 
DNA base modifications. The modifications incurred in DNA of chromatin were 
analyzed by UV and fluorescence spectroscopic techniques. '02-02~-chromatin showed 
hyperchromicity at 260 nm as compared to native chromatin, reflecting the presence of 
single stranded regions and alterations in the structure of chromatin. 'OH-chromatin 
showed hypochromicity at 260 nm reflecting the damage of chromophoric groups and 
structural alterations. The Tm of 'Oj-Or-chromatin was found to be 78°C whereas native 
chromatin showed a Tm of SB^ C. *OH-chromatin showed a Tm of 74*'C. A net decrease of 
5°C in the Tm value of '02-02~-chromatin and a net decrease of 9 ^ in the Tm value of 
'OH-chromatin indicates alterations in the structure and single strand breaks in the DNA 
of chromatin. Nuclease SI sensitivity assay fiirther substantiated the formation of single 
strand breaks. 
Native chromatin, '02-02~-chromatin and *OH-chromatin were used to induce 
antibodies in rabbits and were found to be immunogenic inducing high titre antibodies. 
The modified chromatin was highly immunogenic as compared to native chromatin. The 
antigenic specificity of the induced antibodies was studied by competition ELISA. The 
immunogen showed a high degree of specificity for the induced antibodies. Protein A-
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Sepharose purified immune IgG showed higher specificity as compared to serum. 
Increased immunogenicity of oxygen free radical modified chromatin could be co-related 
to a feature of SLE, wherein chromatin or oligonucleosomes/nucleosomes become 
immimogenic as a result of damage due to ROS against which antibodies are elicited. 
Twenty four SLE sera from patients having high titre anti-DNA autoantibodies 
were studied for their binding to native chromatin, '02-02~-chromatin and 'OH-
chromatin. The binding specificity of SLE autoantibodies was analyzed by inhibition 
ELISA. In direct binding assay, SLE autoantibodies bound '02-02~-chromatin and 'OH-
chromatin in preference to native chromatin. This preference was confirmed by inhibition 
ELISA. The binding specificity of native and modified chromatin with SLE 
autoantibodies was reiterated by gel retardation assay. 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and modified chromatin. For the study, sera of various patients with oral cancer, 
cancer of head and neck, urinary bladder, gall bladder, prostrate, limg, breast, CML and 
Hodgkin's lymphoma were screened. Direct binding ELISA results showed greater 
recognition to '02-02~-chromatin and *OH-chromatin over native chromatin. The binding 
specificity of antibodies in these sera to native and modified chromatin was assessed by 
competitive binding assay. The higher binding to modified chromatin over native 
chromatin by most of the serum samples suggests the involvement of oxygen free radical 
modified chromatin in the production of autoantibodies in cancer patients. 
In conclusion, superoxide anion radical, singlet oxygen and hydroxyl radical cause 
damage to chromatin and render it highly immunogenic. Results indicate possible role of 
modified chromatin in the induction of anti-DNA response in SLE. Higher, recognition of 
oxygen free radical modified chromatin by antibodies in sera of patients with cancer 
and/or SLE suggests fi«e radical induced chromatin damage in patients. It is postulated 
that '02-02~-modified chromatin and *OH-modified chromatin may play a major role in 
the production of SLE anti-DNA autoantibodies and circulating antibodies in cancer. 
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The beautiful double helix structure of DNA was discovered in 1953 by James 
Watson and Francis Crick. DNA contains the instructions to make each one of us. Its 
digital code is similar to binary, except that instead of two alternatives (designated 0 and 
1) it contains four (designated A, C, T and G) (Simon Boa, 1997). It is the position of 
these four bases in the sequence, which generates the information to make a protein. As 
well as generating proteins, DNA is also controlled by them. Specific proteins repair it 
when it gets damaged, tell it when to copy itself and regulate protein production. Some 
proteins physically interact with the DNA and together they are called "chromatin". 
Eukaryotic cells must accomplish the daunting task of packaging an enormous amount of 
DNA into their nucleus, while ensuring the proper expression of a subset of genes and the 
silencing of other regions of the genome. Cells accomplish this feat by packaging DNA 
into chromatin (Rountree et ah, 2001). All of the human genome is packaged into 
chromatin. Although chromatin was historically thought of as an inert repressive 
structure, we now know that it is truly a living vibrant entity (Wolffe, 2001). Chromatin 
consists of DNA and associated proteins. There are two types of proteins in chromatin: 
histones and non-histone chromosomal proteins. Histones are small, well-defined, basic 
proteins, whereas non-histone chromosomal proteins include a large number of widely 
diverse structural, enzymatic and regulatory proteins, most of which are yet to be 
characterized. 
During the 1970s, a combination of physical and molecular biology techniques 
revealed that chromatin consists of a repetitive nucleoprotein complex, the nucleosome 
(Romberg, 1974). The laboratory of Pierre Chambon was the first to name the 
nucleosome (Germond et ah, 1975). The nucleosome particle comprises a histone 
octamer with two copies of each of the histones H2A, H2B, H3 and H4, wrapped by 147 
bp of DNA. In the octamer, histones H3 and H4 are assembled in a tetramer, which is 
flanked by two H2A-H2B dimers. A variable length of DNA completes the second turn 
around the histone octamer and interacts with a fifth histone, named HI (Ballestar and 
Estellar, 2002). The histone octamer wrapped by 147 bp of DNA is called as the 
nucleosome core particle. The DNA between the nucleosomes is called the linker 
segment. The linker segment gives vmfolded chromatin a beads on a string appearance. 
The average linker length is variable in different species, it ranges from zero to a 
maximum of about 100 base pairs. Wolfe in 1993 suggested that linker lengths tend to be 
shortest in the lower eukaryotes, intermediate in plants, and longest in higher eukaryotes. 
Antigenicity of chromatin 
Chromatin has been implicated as an important target of autoantibodies in 
idiopathic and drug-induced lupus for decades, but the antigenicity of chromatin has only 
recently been dissected (Burlingame and Rubin, 1996). Although anti-DNA antibodies 
are considered diagnostic of systemic lupus erythematosus (SLE), they are expressed in 
association with antinuclear antibody specificities, suggesting a role for both generalized 
as well as antigen specific immune abnormalities in their etiology (Pisetsky, 1992; 1997). 
The notion that DNA is immunologically inactive, derives primarily from unsuccessful 
efforts to replicate lupus by immunization of normal animals with DNA (Messina el al., 
1993). However DNA complexes with a synthetic immunogenic peptide Fus-1 induces an 
anti-double stranded DNA response in mice (Desai et al., 1993). This led to the 
conclusion that antigen-drive in lupus involves either a substance other than DNA or 
DNA in the form of nucleosomes. (Burlingame et al., 1993; Mohan et al., 1993). 
The nature of autoantigen that initiates the production of anti-double stranded 
DNA (anti-dsDNA) and anti-histone antibodies in systemic lupus erythematosus has 
remained obscure. Hardin in 1986 noted that patients with SLE responded primarily to 
external features of intact nucleosomal segments of chromatin, since the antibodies 
produced were directed to both histones and dsDNA. 
It has been suggested that in SLE, antibodies to individual histones or to dsDNA 
are minor components of the IgG anti-chromatin (anti-nucleosome) response (Chabre el 
al., 1995). Several studies have reinforced the concept that SLE is an anti-chromatin 
disease; e.g., that the autoimmune response is against chromatin with the development of 
antibodies directed to various epitopes on chromatin including but not limited to DNA 
(Mohan et al., 1993; Burlingame et al., 1993; 1994; Amoura et al., 1994; Chabre et al., 
1995; Tax et al., 1995). The possibility that anti-nucleosomal antibodies may generally 
be involved in nephritis has also been suggested by experimental and clinical studies 
(Burlingame et al, 1994; Kramers et al, 1994; Monestier et a/., 1995; Tax et al., 1995). 
In a clinical study of SLE, antibodies to epitopes on chromatin were foimd to be more 
highly associated with nephritis than antibodies to DNA (Burlingame et al, 1994). The 
genesis of the immune response to chromatin in MRL/Mp-lpr/lpr mice was investigated 
(Burlingame et al., 1993). The results demonstrated that many features of anti-chromatin 
autoantibody production resemble those of an active T cell-dependent immunization 
process, and that antibodies recognize a wide spectrum of epitopes on chromatin. These 
findings imply that chromatin is the structure that initiates the production of anti-histone, 
anti-subnucleosome, and anti-dsDNA autoantibodies. It had been proposed that a defect 
in the catabolism of chromatin may render it immunogenic. A clear example of altered 
DNA/chromatin comes firom examples of patients with drug-induced lupus. Drugs that 
induce lupus like side effects, have been proposed to act in different ways - by inhibiting 
DNA methylation, by inducing a B-DNA to Z-DNA transition, by generating oxidative 
metabolites that can cause massive DNA-damage resulting in release of altered types of 
subnucleosomes, or by inactivating complement C4. Some of these mechanisms may 
generate altered histone or histone/DNA epitopes, thus triggering non-tolerant Th cells 
(Mohan and Datta, 1995). It has been suggested that the change of chromatin's 
antigenicity by environmental factors and genetic background may be the common 
pathway to SLE pathogenesis (Lu et al, 1998). Exposure of autoimmune (NZBXNZW) 
F(I) mice to pristane, a model environmental trigger, synergistically activated the 
production of anti-chromatin/DNA antibodies and dramatically accelerated renal disease 
(Yoshida et al., 2002). Furthermore, it has been reported that chromatin may be one of 
the initiating autoantigens and the possibility that nucleosomes may also be an 
autoantigen in human SLE, is supported by several observations demonstrating the 
presence of oligonucleosome-like structures in plasma from patients with SLE (Mc 
Coubrey et al, 1984; Li and Steinman, 1989; Rumore and Steinman, 1990; Burlingame 
et al, 1993). The formation of anti-nucleosome antibodies and nucleosome-Ig complexes 
is a characteristic feature of MRL/lpr mice. (Licht et al, 2001). Attempts to immunize 
non-autoimmime mice with nucleosomes prepared in vitro have failed, giving support to 
the notion that qualitative modifications of nucleosomes are necessary for autoantibody 
induction (Amoura et ai, 1999). It has been shown that during apoptosis, a series of post-
translational protein modifications, including proteolysis, phosphorylation, oxidation with 
heavy metal etc, may create modified autoantigens that might contribute to the bypass of 
tolerance that is required for autoantibody formation (Utz and Anderson, 1998). An 
inflammatory milieu as well as release of oxygen species (Casciola el ai, 1994), by 
activated phagocytes may affect the immunogenicity of the autoantigens. In this regard, 
DNA damaged by reactive oxygen species in vitro becomes immimogenic and triggers an 
anti-dsDNA antibody response upon injection into rabbits (Cooke et ai, 1997). 
It has been reported fi-om our laboratory that immunization of reactive oxygen 
species modified DNA induces antibodies, exhibits polyspecificity (Ara and Ali, 1992; 
1993; Alam et al., 1993) and recognizes B-, A- and allied conformations of DNA (Ara 
and Ali, 1995). Monoclonal antibodies against ROS-DNA have been used as an immuno-
chemical probe to detect oxidative DNA lesions in cancer, ageing and SLE (Ashok et al., 
1997; Ahmad e/a/., 1998). 
Free radical biochemistry 
The role of fi^e radicals in health and disease has been widely accepted into the 
biochemical and medical orthodoxy. A fi'ee radical is a chemical species, possessing a 
very short half-life that contains one or more unpaired electrons. Free radicals are 
generally very reactive. They can be positively or negatively charged or electrically 
neutral. Free radicals can be formed by homolytic fission of a covalent bond, or by the 
loss/addition of a single electron fi"om/to a normal molecule. The electron transfer is a 
more common process in biological systems than homolytic fission. It is now well 
established that fi-ee radicals and other reactive oxygen species (ROS) are continuously 
produced in vivo, and can damage most cellular components (Martinez-Caynela, 1995). 
Free radicals are generated in vivo by oxidant enzymes, phagocytic cells, redox-cycling 
drugs, ionising radiations etc (Halliwell and Gutteridge, 1989). These radicals cause 
damage to a number of macromolecules including lipids and proteins (Lunec et al., 1985; 
Wolff e^  al., 1986; Lunec, 1990). In consequence, several antioxidant defence systems 
limit their damaging effects and the repair systems prevent the accumulation of 
oxidatively-damaged molecules (Fridovich, 1989; Halliwell and Gutteridge, 1989; Sies, 
1985; 1991). 
The term reactive oxygen species (ROS) includes oxygen-centered radicals as 
superoxide (O-T) and hydroxyl radical (*0H), and also some non-radical derivatives of 
oxygen such as hydrogen peroxide (H2O2), singlet oxygen ('O2), hypochlorous acid 
(HOCl) and ozone (O3), that are involved in oxygen radical production. ROS are highly 
reactive and have extremely short half-lives. There are numerous mechanisms for 
generation of ROS in vivo (Simic et al., 1988; Emerit et al., 1990). It has been proposed 
that many of the damaging effects could be attributed to chemically reactive species like 
superoxide, hydrogen peroxide and hydroxyl radical (Halliwell, 1987; Halliwell and 
Gutteridge, 1989). 
Hydrogen peroxide is ubiquitous in biological systems, formed by the divalent 
reduction of dioxygen or by dismutation of the superoxide anion radicals (Oa") catalysed 
by superoxide dismutase (SOD) (Tachon, 1989). 
2 0 r + 2H^-^H202 + 02. 
Hydrogen peroxide that escapes destruction can act as an oxidizing agent, but is 
not especially reactive. Normal cellular level of hydrogen peroxide is in the range, of 
lO'^ -lO-^ M (Oshino et al., 1973). It can be elevated as a result of inflammation where the 
respiratory burst of phagocytic cells occur (Hammers and Roos, 1985). Its main 
significance lies in it being a source of hydroxyl radicals in the presence of reduced 
transition metal ions via Fenton reaction (Fenton, 1894; Halliwell and Gutturidge, 1990). 
H2O2 + Fe^ ^ / Cu^  -^ 'OH + OH" + Fe^ ^ / Cu^  
In a biosystem, where reducing conditions prevail, Fe^ ^ / Cu"*^  can be regenerated 
easily by an electron donor. 
Hydroxyl radical can also be formed by the interaction of superoxide anion with 
H2O2 through Haber-Weiss reaction (Haber and Weiss, 1934). 
o r + H2O2 -> O2 + H2O + *0H 
Beauchamp and Fridovich in 1970 proposed that toxicity of superoxide radical 
and hydrogen peroxide could involve their conversion into a much more reactive 
hydroxyl radical. Nitric oxide, another reactive oxygen species, interacts with superoxide 
radical to generate peroxynitrite, which in turn forms hydroxyl radicals (Saran et al., 
1990; Inoue and Kawanishi, 1995). 
The hydroxyl radical formed in vivo is an extremely reactive oxidizing radical that 
reacts with most biomolecules at diffusion-controlled rates. It has an extremely short 
half-life. It does not diffuse a significant distance within a cell and is capable of causing 
great damage within a limited radius at its site of production. 
Superoxide anion radical (Oi) is formed in all aerobic organisms. Systems 
generating O "^ have been observed to kill bacteria, inactivate viruses, damage enzymes 
and membrane and destroy animal cell culture (Fridovich, 1978; Halliwiell, 1981). It is 
formed by one electron reduction of oxygen (Florence, 1990; Harris, 1992). Sources of 
superoxide in injured tissues include xanthine oxidase, mitochondria, neutrophils 
catecholamines. Xanthine oxidase is an important source of oxygen derived free radicals 
in reperfused tissue (Granger et al., 1981; Chambers et al, 1985; McCord et al., 1985; 
Hearse et al., 1986). Production of superoxide by mitochondria has been known for 
nearly two decades (Boveris et al, 1976; Turrens and Boveris, 1980). The rate of 
superoxide production by mitochondria increases when the concentration of oxygen is 
increased or the respiratory chain becomes largely reduced (Turrens et al., 1982). 
A potentially large and significant source of free radicals in stimulated neutrophils 
is the activated NADPH oxidase of phagocytic cells. After initiation of the respiratory 
burst, more than 90% of the consumed oxygen can be accounted for the generation of 
superoxide. Production of 0 ^ and H2O2 by neutrophils is enhanced after the cells adhere 
to surfaces or after they are primed with a chemical stimulus (Dahinder et al, 1983). 
The superoxide radical is generated within aerobic biological systems during both 
enzymatic and non-enzymatic oxidation. It is eliminated by conversion to H2O2 and O2 
by superoxide dismutase (Fridovich, 1983; 1986). The finding that O2" is produced by 
some enzymes and is efficiently scavenged by others (McCord and Fridovich, 1968; 
1969) led to the view that Or is an agent of oxygen toxicity. In this view the superoxide 
dismutases (SODs), which catalytically scavenge O2", serve a defensive role (McCord el 
al., 1971). o r is produced m aerobic living cells and it constitutes a threat to these ceils 
and the SODs provide necessary defense. Thus, SOD is abundant in aerobes and is 
scarce, or lacking entirely, in sensitive obligate anaerobes (Mc Cord et al, 1971). 
Singlet oxygen ('O2) is a reactive oxygen species (ROS) involved in a variety of 
biological functions such as gene expression, photoaging and apoptosis (Grether Beck et 
al, 1996; Ryter and Tyrrell, 1998; Zhuang et al, 1999; Krutmann, 2000). It was 
discovered by Kantsky and deBruijn in 1931. 'O2 is a chemically aggressive oxygen 
species, capable of attacking cellular components critical for cell survival. Ever since its 
discovery, its production by photosensitization reactions (including those involving 
endogenous sensitizers) has been intensively investigated but more recently attention has 
been drawn by studies showing that 'Oa can also be generated in the absence of light, 
e.g., by lipid peroxidation, by a number of enzymatic reactions (Gille and Joenje, 1991) 
or by interaction between superoxide and reduced glutathione (Wefers and Sies, 1983). 
Singlet oxygen is also produced during photo-oxidation of a variety of biological 
compounds and xenobiotics (Krinsky, 1977; Krasnovsky, 1991). It has been established 
that human leukocytes can generate 'O2 (Kanofsky et al, 1988). Singlet oxygen is 
relatively long-lived, with half- times in the range of 4-50 jis, so that diffusion of singlet 
oxygen is possible within a radius estimated to be in the range of 100 A (Schnuriger and 
Bourdon, 1968; Moan, 1990). Reactions of 'O2 are physical and/or chemical (Kasha and 
BChan, 1970; Krasnovsky, 1979). The physical reactivity is characterized by 
photoemissive decay. The chemical reactions are manifold, including, addition to olefins, 
forming dioxetanes, allylic hydroperoxides ('ene reaction'), and endoperoxides, as well 
as oxidation of sulfides or phenols to form sulfoxides or hydroperoxydienones 
(Wasserman and Murray, 1979; Frimer, 1985; Aubry, 1991). This chemical reactivity is 
the basis of biological damage inflicted by singlet oxygen. 
Free radical production in cells 
Production of fi-ee radicals in animal cells can either be accidental or deliberate. 
The major source of free radicals in cells is electron 'leakage' from electron transport 
chains, such as those in mitochondria and in the endoplasmic reticulum to molecular 
oxygen, generating superoxide. Auto-oxidation of certain compounds including ascorbic 
acid (vitamin C), thiols (e.g. glutathione, cysteine), adrenaline and flavin co-enzymes is 
also a good source of superoxide. Activated phagocytes also deliberately generate 
superoxide as part of their bactericidal role (Babior, 1978). Several toxic foreign 
compounds enhance the free radical production in cells. Flavin oxidases located in the 
peroxisomes also produce superoxide or hydrogen peroxide. The generation of reactive 
free radicals overwhelms the antioxidant defence in the liver and results in serious tissue 
damage. In many cases, the free radical production may be secondary to the initial toxic 
mechanism, a consequence rather than the cause of cell damage. 
Biological effects of free radicals 
The activated oxygen species, including superoxide anion radical, hydrogen 
peroxide, hydroxyl radical and singlet oxygen can be generated by the incomplete 
reduction of oxygen to water during respiration, by exposure to radiation, lights, metals, 
redox active drugs or by release from stimulated macrophages (Sies, 1986). These species 
may reach the genetic material yielding DNA damage by a variety of mechanisms 
(Halliwell and Aruoma, 1991). 
Hydroxyl radicals resulting from oxidative metabolism or endogenous sources 
such as ionizing radiations or redox cycling drugs have been shown to induce base 
damage (Aruoma et al., 1989, 1991; Blakely et al., 1990; Gajewski et al., 1990), strand 
breakj^e (Bradley and Erickson, 1981; Kohen et al., 1986), DNA-protein cross links 
(Mee and Adelstein, 1979, 1981; Lesko, 1982; Chiu et al., 1986, 1993; Gajewski et al., 
1988; Nackerdien et al, 1991), and other types of DNA damage (Hutchinson, 1985 and 
von Soimtag, 1987). Hydroxyl radical attacks all constituents of DNA producing a 
multiplicity of chemical changes in the deoxyribose, pyrimidines and purines (von 
Sonnt^, 1987). Hydroxyl radicals are also believed to be responsible for a major part of 
the chromatin damage (Brawn and Fridovich, 1981; Halliwell, 1987; NassiCalo et al., 
1989; Friedbergera/., 1995). 
The damaging effects of hydroxyl radicals in cells depend on their proximity to 
DNA. In most cases, however, the reaction of hydroxyl radicals with chromatin can be 
verified only indirectly, i.e. through the damage hydroxyl radical produces on 
chromosomal proteins and DNA. Direct detection of hydroxyl radicals in the presence of 
DNA has been very difficult to achieve, as these radicals are very short lived and highly 
reactive towards biomolecules (Pryor, 1988). Nackerdien et al in 1991 demonstrated the 
increase in production of DNA base products in isolated human chromatin such as 
cytosine glycol, formamidopyrimidines and 8 hydroxypurines arising firom reactions of 
hydroxyl radical with the DNA bases. 
The superoxide anion radical is formed in almost all aerobic cells. Numerous 
studies of the effects of 02~ flux upon erythrocytes have been reported. 1, 
4-napthoquinone-2-sulfonate reacts with oxyhemoglobin yielding methemoglobin plus 
0*2~ and can be used to increase O'-T production in erythrocytes (Goldberg and Stern, 
1976). Dismutation of 02~ yields hydrogen peroxide (Halliwell and Gutteridge, 1989). 
The latter compound can cause formation of modified bases fi^om pyrimidines and 
purines in the presence of metal ions in isolated DNA (Aruoma et al, 1989, 1991; 
Blakely et al., 1990), in isolated mammalian chromatin (Dizdaroglu et al., 1991 b; 
Nackerdien et al., 1991), and in intact mammalian cells (Dizdaroglu et al., 1991 a). 
Several studies have implicated both 02~ and H2O2 in the lung damage caused by 
hyperoxia. 
Singlet molecular oxygen ('O2) has also been implicated in several biological 
processes that may lead to genetic damage. DNA is one of the main targets of 'O2, it has 
been demonstrated that 'O2 reacts preferentially with guanine residues either as free 
nucleosides (Cadet et al., 1983) or as components of the DNA molecule (Menck et al., 
1993), yielding a variety of DNA lesions selectively at guanine sites. These include DNA 
cleavage (Devasagayam, 1991), alkali and piperidine-labile sites including abasic sites 
(Blazek et al, 1989), cyanuric acid (Cadet et al, 1983), 2,6-diamino-4-oxo-5-
formamidopyrimidine (FapyG) and 7,8-dihydro-8-oxodeoxyguanine (8-oxodG) (Floyd et 
al, 1989). Studies have demonstrated that *02 also induces single-strand breaks in DNA 
(Blazek et al, 1989). The harmfiil effects of 'O2 are not limited to nucleic acids. Its 
reactivity with amino acids as well as with lipids, leading to damage to cell membranes, 
is also well documented (Frimer, 1985). Singlet oxygen inhibits platelet aggregation. 
Studies (Stief et al., 2001) have demonstrated that 'O2 inhibits and reverses platelet 
aggregation. 
There are several lines of evidence supporting the idea that singlet oxygen is a 
major cytotoxic species towards eukaryotic cells (Eisenberg et al, 1984; Dubbelman et 
al, 1988), bacteria (Epe et al, 1989) and viruses (Houba-Herin et al, 1982). h has been 
suggested that damages caused in the nucleus by singlet oxygen could be, to some extent, 
responsible for cell inactivation (Ito, 1974; Kobayashi and Ito, 1976). Some evidence 
showing that 'O2 can promote mutagenic effects has been provided for a variety of 
organisms ranging from yeast (Ito and Kobayashi, 1977) and bacteria (Gutter et al, 1977) 
to viruses (Piette et al, 1978). Decuyper-Debergh et al (1987) demonstrated that Guanine 
oxidation products induced by singlet oxygen constitute premutational lesions if they are 
not repaired. 
A large nimiber of other modifications of bases and sugars have been identified 
(Dizdaroglu, 1991; 1994). The yield of the individual DNA modifications is highly 
dependent on which reactive oxygen species are involved. Thus, whereas singlet oxygen 
induces preferentially 8-oxo-dG (Epe, 1991), superoxide has low reactivity (Fischer-
Nielsen et al, 1994), and hydroxyl radical can cause almost any modification 
(Dizdaroglu, 1991). 
Antioxidants 
Aerobic organisms have potent antioxidant defences whose role is to neutralize 
and minimize the potentially cytotoxic and genotoxic effects of reactive oxidants. 
Antioxidants are key line of defence capable of scavenging free radicals by preventing 
radical formation, intercepting radicals from further activity (Cotgreave et al, 1988), or 
participating in repair of damage caused by free radicals (Sies, 1993). Antioxidant 
defences may be primary or secondary. The defences that directly scavenge, H2O2 and 
'OH are known as primary antioxidant defence. Secondary antioxidant defences consist 
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of the repair mechanisms that act on biomolecules that have undergone oxidative 
damage. 
There may be enzymatic or non-enzymatic antioxidant defences. Enzymatic 
antioxidant defences include superoxide dismutase (SOD), catalase, glutathione 
peroxidase etc. Superoxide dismutase catalyses the dismutation of O^ to H2O2 
(Fridovich, 1989). 
o r + o r ^^^ > H2O2 + O2 
The concentration of SOD is high in tissues with high oxygen utilization and is 
inducible by raising tissue p02. 
Catalase mediates the detoxification of H2O2 from the cell when it is present in 
high concentrations. Catalase is a heme protein that decomposes H2O2 to O2 and H2O. 
2H2O2 catalase ^Q^ ^ 2H2O 
Catalase is present in the cytosol, mitochondria and other organelles, but is 
difficult to detect in an extracellular environment. 
Selenium dependend glutathione peroxidase (GSHpx) catalyzes the reduction of 
H2O2 and organic fi-ee hydroperoxides requiring glutathione as substrate (Emster, 1987). 
H2O2 + 2GSH ^ ^ ^ P ^ ) GSSG + 2H20 
(reduced (oxidized 
glutathione) glutathione) 
ROOH + 2GSH ^ ^ ^ P ^ > GSSG + ROH + H2O 
Glutathione reductase reduces oxidized glutathione utilizing NADPH generated 
by various systems. 
GSSG + NADPH + H^  > 2GSH + NADP^ 
Normally, most of the intracellular glutathione is in its reduced form. Increased 
intracellular concentrations of H2O2 results in a drop in GSH/GSSG ratio, which serves to 
detect intracellular oxidative stress (Tribble and Jone, 1990). Other enzymatic proteins 
such as DT-diaphorase or epoxide hydrolase are also considered to be primary 
antioxidant defences (Emster, 1987; Lind et al., 1990). 
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There is no enzymatic mechanism to directly protect against 'OH because of its 
extremely high reactivity and rapid consumption. The cell possesses non-enzymatic 
antioxidant defence mechanisms, which scavenge *0H. These scavengers may be 
hydrophillic (ascorbate, urate, glutathione) or hydrophobic (a-tocopherol, P-carotene). 
Glutathione, vitamin C, uric acid, taurine, hypotaurine are some of the small molecules 
widely distributed in biological systems, which scavenge oxygen free radicals non-
enzymatically. Vitamin E (a-tocopherol), the major lipid-soluble antioxidant protects 
against lipid peroxidation by donating a hydrogen ion to oxygen free radical. The 
resultant tocopheryl radical may be reduced by the ascorbic acid-GSH redox couple 
(Cadenas, 1989; Empey et al., 1992). a-tocopherol is key 'OH scavenger and chain 
breaking antioxidant in biological membranes (Niki e( ai, 1988). Vitamin E is important 
in protecting tissue from a variety of physio-pathological insults, which results in 
enhanced tissue reactive oxygen species generation (Chow, 1991). P-carotene, the most 
efficient scavenger of singlet oxygen, has a synergistic action with vitamin E (Machlin 
and Bendich, 1987; Bendich and Olson, 1989; Di Mascio et al., 1991). 
The various defences are complementary to each other since they metabolize or 
scavenge different species in different cellular compartments. 
Autoimmunity 
The ability to distinguish self from non-self is a seminal feature of the immune 
system. Central T-cell tolerance to self-antigens is mediated either by elimination or 
fimctional inactivation of self-reactive lymphocytes (Zouali, et al., 1993). Disruption of 
self-nonself discrimination leads to autoimmunity (Deodhar, 1992). Autoimmunity is a 
state wherein the host mounts an immune response to self There are at least four possible 
immune states in an autoimmune response (Brickman and Shoenfeld, 2001) (Table 1). 
Normally, the immune system responds to a wide variety of foreign insults, such as 
bacteria, viruses, other parasites and internal changes such as cancer, while not 
responding to one's own self antigens. During immunological disbalance, as a result of 
intemal threat, the body's own tissue components become reactive and may result in the 
initiation of autoimmune process / diseases (Deodhar, 1992). There is a delicate balance 
13 
TABLE -1 
Possible immune states in an autoimmune response 
1. Healthful immune state in an otherwise normal host: Anti-idiotypic antibodies 
modulating an acute antibody response following an acute, self-limited infection. 
2. Healthful immune state in an abnormal host: Anti-tumour antibodies, cellular 
response to malignancies, cellular response to intracellular infections. 
3. Detrimental immune state in the abnormal host: Immune response to malignant 
cells cross reacts with normal tissue antigens causing an autoimmune disorder. 
4. Detrimental immune state in the otherwise normal host: Results in classic 
autoimmune, clinico-pathologic conditions such as lupus, diabetes or thyroiditis. 
5. Autoimmune diseases: Result due to the disruption of self-nonself discrimination. 
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between autoimmunity and autoimmune disease. Autoimmunity may be envisioned a 
normal event, while autoimmune diseases result from an aberration of this normal 
phenomenon. Autoinununity, namely the ability to recognize various forms of self, is a 
normal function of the immune repertoire. In contrast, autoimmune disease is the 
clinicopathologic state wherein the host mounts a detrimental response to self (Brickman 
and Shoenfeld, 2001). 
The generation of autoimmunity is multifaceted process in which the role of the 
autoantigen needs to be carefully defined (Zouali et al., 1993). Autoimmune diseases are 
characterized by more or less systemic chronic inflammatory processes, possibly leading 
to tissue damage (Lorenz et al., 2001). 
Factors associated with autoimmune disease 
Autoimmune disease is multifactorial. Criteria for classification of a disease as 
autoimmune have been established (Rose and Bona, 1994) and these research criteria 
exist for the classification of most autoimmune disorders. The factors contributing to the 
development of such diseases continue to expand. The major factors associated with the 
development of autoimmunity maybe divided into genetic, immunologic, hormonal and 
environmental (Brickman and Shoenfeld, 2001). 
(i) Genetic factors 
Autoinmiune diseases show a highly significant familial predisposition 
(Hochberg, 1987; Amett, 1992). Clinicians treating patients with autoimmime disorders 
have long been struck by the finding that such patients frequently have relatives with the 
same or with other autoimmime disorders (Shoenfeld and Isenberg, 1989). The 
involvement of genetic factors has been linked to the human lymphocyte antigen (HLA) 
system, particularly the HLA-DR sublocus. The HLA genes function as secondary genes 
to allow expression of specific autoantibody or the respective disease state (Bias et al., 
1986). The HLA molecules that are present on the surface of all nucleated cells and 
platelets are encoded for within the major histocompatibility complex (MHC) on the 
short arm of chromosome 6 in humans (Burnett, 1959). The initiation of an autoimmune 
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response requires that the self-reactive T cells interact with self-antigen and HLA class II 
antigen complex with sufficient avidity for the development of autoantibody in 
subsequent autoimmune diseases. The association between certain autoimmune diseases 
and HLA antigens (Braun and Zachary, 1988) such as SLE DR2 and DR3, Sjogren's 
syndrome and DR2 and for DR3, insulin-dependent diabetes mellitus or diabetes Type I 
DR4 and DR3, Grave's disease and DR3, myasthenia gravis and DR3, rheumatoid 
arthritis and DR4 are well documented. However genetics is not the final determinant of 
autoimmune disease development (Brickman and Shoenfeld, 2001). If a single gene were 
solely responsible for autoimmune diseases, homozygotic twins would show 100% 
concordance, not, for example, the 57% concordance reported in lupus and the 34% 
reported in rheumatoid arthritis (Winchester and Lahita, 1987). 
(ii) Immunologic factors 
Cellular immunity with anti-self properties is part of the normal immune 
response. Low affinity polyspecific antibodies and idiotypic antibodies may play a role in 
immunoregulation. Malregulation of immune system depends on multiple components of 
feedback regiilation system including T cells, B cells and idiotypes (Shoenfeld and 
Schwartz, 1984). In a wide a variety of autoimmune diseases, the regulatory failure result 
in significant decrease in T-suppressor cell numbers and activity, thereby imbalancing the 
T-helper/T-suppressor cell ratio. The increased T-helper/T-suppressor cell ratio had been 
noted in a wide variety of autoimmune diseases, such as, SLE, Sjogren's syndrome, PSS 
or scleroderma, rheumatoid arthritis, pernicious anemia, multiple sclerosis, immune 
complex mediated renal diseases, immunologic skin diseases and many others. 
Immunologic cross reactivity and molecular mimicry has been an important phenomenon 
in autoimmune diseases. It has been suggested that the degree of sequence conservation 
between host and a given infectious agent, heat shock proteins, because of molecular 
mimicry, may provide the link between infection and subsequent autoimmunity. 
Some persons may mount an immime response against self and others do not 
because HLA molecules from different individuals display different portions of the 
antigen to T cells. Thus, one person's HLA molecule may bind a self-mimicking portion 
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while another's may not. Polyclonal B cell activation has been proposed as one possible 
mechanism that may be responsible for the over-activation of B cells and production of 
autoantibodies in certain autoimmune diseases, particularly SLE (Dziarsky, 1988; 
Klinman et al, 1990; Steinberg, 1992). In autoimmune prone individuals, B cells are 
hyper-responsive to polyclonal activators and undergo initial activation, followed by 
expansion of auto reactive clones, under the influence of exogenous or endogenous 
polyclonal activators like Epstein Barr Virus (EBU) and its components and endotoxin or 
lipopolysaccharide (LPS), certain bacterial agents and drugs. 
One hypothesis called as the 'modified self hypothesis suggests that 
autoimmimity may arise as a result of an immune response against modified self 
determinants (neo-self determinants) such as new determinants created on somatically 
mutated antibodies during the maturation of the immune response. Rheumatoid factors 
(RFs), which are anti-IgG Fc autoantibodies induced transiently during an immune 
response, presumably because neo-antigenic determinants are exposed on antigen 
complexed IgG. Glycosylation defects in IgGs have also been proposed as playing a role 
in RF induction, although the specificity of this phenomenon is imcertain (Tsuchiya et al., 
1993). Complement deficiencies (Fries et ah, 1986) associated with particular HLA 
phenotypes may cause immune disease via inefficient opsonization of infectious agents 
or slowed clearance of immune complexes (Frank et al., 1983). "Nephritic factor" 
referring to an antibody against neo-antigenic determinants reveals the complement 
protein C3 during complement activation (Spitzer et al., 1992). Other possibilities of 
creating non-self determinants occur through building of drugs or other haptenic groups 
to self-molecules, as well as through molecular modifications introduced, for example, by 
gene mutations. 
(ill) Hormonal factors. 
Hormones are a significant factor in the development of autoimmune disorders 
(Ahmed and Talal, 1999; Lahita, 1999). Clinicians caring for patients suffering from 
these disorders were the first to bring to the scientific community's attention the 
predilection of some (e.g. rheumatoid arthritis and lupus), but not all, autoimmune 
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diseases for females. Patients bom with Klinefelter's syndrome, a feminising genotype, 
also have an unusually high prevalence of lupus (Ortiz and LeRoy, 1969). Animal models 
of autoimmune diseases show similar predilections. Despite this, the role sex hormones 
play in autoimmune disease is unclear. In humans as well as in animal models, some 
autoimmune diseases show a predilection for males rather than for females. Danazol, a 
semi-synthetic androgen occasionally used in treatment of autoimmune disorders, may 
induce lupus in some patients (Guillet et ai, 1988). Other hormones including 
progesterone (VanVoIIenhoven and McGuire, 1994) and prolactin (Walker et al., 1998) 
appear to have immunoregulatory properties. 
(iv) Environmental factors 
Environmental factors have been implicated in autoimmune diseases including 
infectious agents, medications, chemicals, toxins and ultraviolet light to name but a few 
(Aharon and Shoenfeld, 1998; Saraux el al., 1999). Smoking and obesity may increase 
the risk of RA (Karlson et al., 1999; Shovman and Shoenfeld, 2000). Here, the 
multifactorial nature of autoimmune disorders also become evident while ultraviolet light 
is known to trigger lupus (McGrath, 1999), it has been very effectively used to treat 
psoriasis, another autoimmune disease (Halpem el al., 2000). 
D-pencillanmine, a medication formerly used to treat several immune diseases 
including RA, scleroderma and primary biliary cirrhosis, has been implicated in the 
development of autoimmune diseases such as lupus and glomerulonephritis (Brik et al., 
1995). Physical and psychological stresses have also been implicated in the development 
of autoimmune diseases (Gaillard and Spinedi, 1998). 
The common thread among all the hypotheses of autoimmune diseases is the loss 
of energy to innocent autoantigens or the loss of tolerance to self. However, to date no 
single theory adequately explams the development of all autoimmune diseases and, at 
least in humans, no one theory adequately explains the development of particular 
autoimmune disorder. Therefore, it may be stated that the evolution from autoimmunity 
to autoimmune disease is multifactorial (Brickman and Shoenfeld, 2001). 
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Autoimmune diseases may be classified, somewhat arbitrarily, into organ specific 
and systemic autoimmune diseases (Table 2). There are autoimmune diseases in which 
the autoantigen is known, like myasthenia gravis (acetylcholine receptor), Grave's 
disease (TSH-receptor), or encephalomyelitis disseminata (myelin basic protein). 
Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder 
characterized by a marked diversity of organ involvement and fluctuations in disease 
activity (Min et al., 2002). It is a relatively common non organ-specific disease. 
Characteristically, inflammatory skin lesions and multiple organ damage occur. In 60-
70% of cases, renal involvement complicates the systems and its severity largely 
determines prognosis (Zouali, 2001), Since these systems are associated with 
autoantibody production against a myriad of nuclear antigens, SLE has become a 
prototype of systemic autoimmune diseases (Hahn, 1998; Davidson and Diamond, 2001). 
With a prevalence comparable to that of multiple sclerosis, it predominantly affects 
women, with a female/male ratio of approximately 9/1 (Zouali, 2001). SLE is the most 
representative of all autoimmime diseases because it may affect any organ of the body 
and display a wide range of clinical manifestations (Cervera et al, 1993) and various 
immunologic disorders, including production of autoantibodies, formation of immune 
complexes, decreased serum complement levels, and lymphocytopenia (Kato et al., 
2000). 
SLE is characterized by the production of a variety of autoantibodies against 
nuclear, cytoplasmic and cell surface antigens. The cellular and molecular mechanisms 
that are responsible for the production of antinuclear antibodies in this disease and the 
way in which these antibodies participate in tissue destruction remain highly 
controversial (Ravirajan et al., 2001). 
One of the first autoantibody populations to be characterized was antibodies to 
native DNA, which are strongly correlated with the diagnosis of SLE (Tan, 1989). In 
1997, the discovery of autoantibodies reactive with DNA celebrated its 40* anniversary. 
Over these four decades, perhaps no other single spontaneously produced autoantibody 
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TABLE - 2 
Classification of autoimmune diseases 
Organ specific autoimmune diseases 
Grave's diseases 
Hashimoto's thyroiditis 
Rheumatoid arthritis 
Myasthenia gravis 
Pernicious anemia 
Addison's disease 
Insulin dependent diabetes mellitus 
Primary biliary cirrhosis 
Systemic / non-organ specific autoimmune diseases 
Autoimmune hepatitis 
Autoimmune hemolytic anemia 
Idiopathic thrombocytopenic purpura 
Autoimmune gastritis 
Multiple sclerosis 
Ulcerative colitis 
Systemic lupus erythematosus 
Sjogren's syndrome 
Systemic sclerosis 
Mixed connective tissue damage 
Systemic vasculitis 
Behcet's disease 
Antiphospholipid syndrome 
Polymyositis / Dermatomyositis 
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has drawn such a wide scientific interest from basic immunologists and clinicians, 
particularly with respect to the mechanisms that lead to anti-DN A antibody formation and 
pathogenicity in systemic lupus erythematosus (Antonio et al., 1998). Anti-dsDNA 
antibodies are a hallmark of SLE (Tan et al., 1966; Arana and Seligmann, 1967), and 
anti-dsDNA/DNA immune complexes have long been considered responsible for the 
development of lupus nephritis. The presence of anti-dsDNA antibodies in the serum of 
SLE patients constitutes one of the eleven American Rheumatism Association (ARA) 
criteria for the diagnosis of SLE (Tan et al., 1982). It defines a clinical subset of the 
disease and provides information of the prognosis and response to treatment (Pisetsky, 
1992). As structural studies with a growing number of monoclonal anti-DNA antibodies 
have progressed, it has emerged that anti-dsDNA antibodies have all the characteristics of 
those produced in an antigen-stimulated secondary immune response. They are 
predominantly of IgG isotype, are highly oligoclonal, and have numerous somatic 
mutations in their VH regions, features typical of an antigen driven response (Eilat and 
Fischel, 1991; Tillman et al., 1992; Radic and Weigert, 1994). 
Autoantibodies to histones were found to be present as often as anti-DNA 
antibodies in SLE (Gioud et al., 1982; Hardin and Thomas, 1983; Monestier and Kotzin, 
1992). Several studies have demonstrated that anti-native DNA antibodies are commonly 
copresent with anti-histone antibodies in SLE sera (Costa and Monier, 1983; Krippner el 
al., 1984; Kohda et al., 1989). Anti-histone antibodies may react with each of the five 
histones (Hardin and Thomas, 1983; Portanova et al., 1987; Muller et al., 1989; 
Monestier and Kotzin, 1992) and with H3-H4 and H2A-H2B complexes (Burlingame el 
al., 1994). The importance of anti-histone antibodies in SLE is confounded by 
discrepancies in their reported prevalence, isotype, specificity and correlation with 
symptoms (Monestier and Kotzin, 1992; Rubin, 1992). As a result, little insight into their 
diagnostic ability, pathogenic significance or origin in SLE has been derived (Suzuki et 
al., 1994). 
The concomitant presence of autoantibodies to histones and to DNA in the same 
individual led to the early hypothesis that these two populations were linked sets of 
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antibody and were induced by a unique antigen composed of both dsDNA and histones 
(Hardin, 1986). 
Serum antibodies reacting with chromatin or its predominant components, 
histones and DNA, have been found in SLE, drug induced lupus, several other human 
disease states and in murine models of SLE (Schwartz and StoUar 1985; Theofilopoulos 
and Dixon, 1985; Costa and Monier, 1986; Fisher et ai, 1988; Portanova et al., 1988; 
Burlingame and Rubin, 1991). Several studies have demonstrated that the autoimmune 
response is agmnst chromatin with the development of antibodies directed to various 
epitopes on chromatin including but not limited to DNA (Burlingame et al., 1993; 1994; 
Mohan et al., 1993; Amoura et al., 1994; Chabre et al., 1995; Tax et al., 1995). A central 
role for chromatin in autoimmune responses to histones and dsDNA in human lupus has 
been suggested (Burlingame et al., 1994). It has been suggested that the nucleosome, the 
fundamental repeating unit of chromatin, could be a major autoantigen in lupus. 
Circulating nucleosome oligomers have been demonstrated in the plasma of SLE patients. 
(Rumore and Steinman, 1990). Studies have revealed that anti-nucleosome antibodies 
occur early in life, before the emergence of anti-dsDNA and anti-histone antibodies 
(Burlingame et al., 1993; Amoura et al., 1994). 
The nucleosome (or chromatin) is emerging as the most reactive substrate among 
the nuclear antigens, 70-80% of SLE patients being positive (Burlingame et al., 1994; 
Wallace et al., 1994; Chabre et al., 1995; Lefkowith el al., 1996; Amoura et ai, 1997). 
Anti-nucleosome antibodies might be a good marker of anti-DNA negative SLE cases 
(Amoura et al., 1999; Min et al., 2002). 
Other autoantibodies that have been demonstrated in sera of SLE patients include 
anti-ribosomal P protein antibodies, anti-Ro/La autoantibodies, anti-neutrophil 
cytoplasmic antibodies, anti-phospholipid/cofactor antibodies, antinuclear antibodies 
(reacting with ssDNA, dsDNA, ribonucleoprotein, Sm etc) (Anasuma etai, 1997; Emlen 
and O'Neill, 1997; Font et ai, 1997; Guerin et al., 1997; Lang et al., 1997; Villarreal et 
al., 1997; Wang etal., 1997; Anderson et al., 1998). 
Anti-DNA antibodies are deposited in kidneys of patients and mice with lupus 
diseases. In lupus, nucleosomes could be at work in the induction of anti-DNA antibodies 
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(Mohan et al., 1993), and in the development of kidney lesions (Tax et al., .1995). 
Observations suggest that cationic residues of histones could bind to anionic heparan 
sulphate and mediate the glomerular deposition of autoantibodies. Deposition of histones 
has been foimd in glomeruli from mice and himians with lupus (Schmiedeke et al., 1992). 
The mechanisms by which the nucleosome-triggered deposition of pathogenic antibodies 
is mediated (immime complex deposition or/and local formation) is still a matter of 
debate (Foumie, 1996). The issue of whether lupus autoantibodies are the result of 
antigen stimulation or of polyclonal activation, has been addressed by a number of 
investigators. B-lymphocytes from SLE patients generally appear to be more activated 
than B cells from healthy individuals. Further molecular studies of autoantibody genes 
revealed that in both the human disease and in experimental models of lupus, production 
of autoantibodies is antigen driven (Shiomchik et al., 1990; Manheimer-Lory et al., 1991; 
Winkler era/., 1992;Zouali, 1992; 1997). 
Autoantibodies and B cells have been in the lupus limelight for decades, but now 
T cells have been studied extensively in SLE (Spronk et al., 1996). T cells have been 
cloned from lupus-prone mice, and stimulate the production of anti-DNA antibodies and 
renal lesions when injected in vivo. In mice and humans with lupus, the histone/DNA 
binding T cells are activated, express the CD40 ligand, and have the potential to trigger B 
cells to produce antibodies. Various T cell abnormalities have been observed in SLE 
(Tsokos, 1992; Horwitz and Stohl, 1993; Via and Handwerger, 1993; Dayal and 
Kammer, 1996; Datta et al, 1997a; Horwitz, 1997; Kovacs, 1997). The T cells of patient 
with SLE show impaired in vitro proliferation in response to mitogens, antigens and 
allogenic major histocompatibility complex (MHC) molecules (Via and Handwerger, 
1993; Dayal and Kammer, 1996; Datta et al, 1997a; Horwitz, 1997). 
The complement system is of central importance in SLE. Acquired complement 
deficiency is a common finding in SLE. Low C3 and C4 complement suggests, that there 
is activation of the classic complement pathway in active immune complex disease. 
Measurement of classic pathway complement components is important in the diagnosis 
of SLE and for monitoring of immune complex mediated manifestations especially 
proliferative glomerulonephritis (Sturfelt, 2002). 
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Oxygen free radicals in SLE 
Oxygen derived species such as superoxide (OD and H2O2 are produced in 
mammalian cells as a result of aerobic metabolism (Fridovich, 1978; Halliwell and 
Gutteridge, 1985). Excess generation of these species can result in damage to 
macromolecules, including DNA (Aruoma et al., 1989b) and have been implicated in 
etiology of many human diseases (Halliwell and Gutteridge, 1990; Lunec, 1990), 
including SLE (Blount et al., 1994; Cooke et al., 1997). DNA damage by reactive oxygen 
species (ROS) has been found in the development of autoimmune diseases, such as SLE 
(Blount et al., 1991). The process may involve the release of ROS intermediates from 
activated phagocytic cells, their passage through cell membranes, and finally reaction 
with nuclear DNA (Bashir et al., 1993) producing altered DNA, stimulating DNA-
antibody production. The development of autoantibodies in SLE has been supported by 
the enhanced reactivity of SLE anti-DNA antibodies to ROS modified DNA and 
polynucleotides (Blount et al, 1989; 1990; Alam et al, 1993; Ara and Ali, 1993; Ahmad 
et al, 1997; Cooke et al, 1997). The detection of 8-oxo-dG in the immune complex 
derived DNA of SLE (Lunec et al, 1994), reinforces the evidence that ROS may be 
involved in SLE. ROS modified DNA may play a significant role in the generation of 
immune complexes, which are of recognized importance in the pathogenesis of SLE 
(Lisitsyna et al, 1996; Cooke et al, 1997). 
Approach to therapy 
Despite the power of modem molecular approaches and persisting investigative 
efforts, lupus remains an enigmatic disorder. Corticosteroids and cyclophosphamides are 
widely used for the treatment of SLE, which exert immunosuppressive activities 
(Kroemer and Martinez, 1994). However, their utility is restricted by their undesirable 
side effects including infection, premature cardiovascular mortality, infertility, and 
neoplasia (Hellmaim et al, 1987; Pistiner, 1991). Immunosuppressive drugs with a high 
desired/adverse reaction ratio are awaited. It has been shown that FTY720 [2-amino-2-(z-
{4-octyl-phenyl}ethyl)-l,3-propane-diol hydrochloride], a novel immvmosuppressant is 
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efficacious for the treatment of experimental SLE in MRL/lpr mice (Okazaki et al., 
2002). 
If lupus is due to a loss of self-tolerance, it may be possible to design a more 
general therapy to restore self tolerance (Steinberg, 1994). Gene therapy, another 
approach to curing of lupus has been performed successfully in mice. Provided that 
kidneys are not yet irreversibly damaged, the use of human soluble or chimeric receptors 
(constant part of human IgG heavy chain linked to the human soluble IFN-receptor) 
(Kurschner et al., 1992 a, b) is an attractive prospective in the treatment of autoimmune 
glomerulonephritis in human SLE (Ozmen et al., 1995). Specific immunotherapy for 
human SLE can be designed based on the studies of Datta et al., 1997b. Once the 
pathogenic Th cell epitopes in the nucleosomes are identified, autoantigen mediated 
signal 1 to the Th cells could be blocked, in combination with anti-CD40-L therapy to 
block CD40-mediated signal 2 to the pathogenic autoantibody producing B cells. Thus 
instead of blocking signals 1 and 2 for either the autoimmune T or the autoimmune B 
cell, both of these major players in the pathogenic unit could be blocked by combination 
therapy. 
Cancer 
Carcinogenesis is the malignant transformation of a cell or group of cells (Farber 
and Cameron, 1980; Potter, 1983; Farber, 1984). Almost every tissue in the body can 
spawn malignancies, some even yield several types, with each cancer having unique 
features. The genes implicated in the malignancy are often modified forms of the human 
genes. The activation of proto-oncogenes into oncogenes, the product of which when 
altered contribute to malignancy. Mutation can also convert proto-oncogene into 
carcinogenic oncogenes. 
As with other chronic diseases, cancer too has a multifactorial etiology which 
include both genetic and environmental factors (Gourley et al., 1992). Genetic influence, 
though long been suspected in incidence of cancer, is less conspicuous and more difficult 
to identify (Clemens, 1991). The environmental factors are responsible for maximum 
percentage of all human cancers. 
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Among the environmental factors alcohol consumption is associated with cancer 
of oesophagus, liver and rectum (Kabat et a/., 1986; Eskelson et al., 1993). Tobacco 
consumption is the major cause of cancer of lung, larynx, mouth, pharynx, bladder, 
pancreas and probably Kidney (WHO, 1983). Dietary factors such as food additives, 
contaminants, high fat diet have been, related to cancer (Ames, 1983) Viruses such or 
Hepatitis B and C are related to hepatocellular carcinoma (Blumberg et al., 1975). 
Occupational exposures to benzene, arsenic, cadmium, chromium etc have also been 
known to cause cancer (Kasai and Nishimura, 1984; Frenkel, 1992; Kolachna et al., 
1993; Lagorio et al., 1994). Other environmental factors such as sunlight, radiations, 
pesticides and medications are also known to be related to cancer (Ananthaswamy and 
Pierceall, 1990; Liehr, 1997). 
Most of the exogenous carcinogens act via production of reactive oxygen species 
(Frenkel, 1992; Leanderson, 1993; Feig et al., 1994; Erhardt et al., 1997) 
Oxygen free radicals in cancer 
Oxygen derived species such as superoxide anion radical, hydrogen peroxide, 
singlet oxygen and hydroxyl radical are well known to be cytotoxic and have been 
implicated in the etiology of a number of human diseases including cancer (Cerutti, 1985; 
Halliwell and Gutteridge, 1989). 
An increased production of oxygen derived species with in cells frequently leads 
to DNA dam^e by a variety of mechanisms and such species can probably initiate and 
promote cancer (Cerutti, 1985; Halliwell and Aruoma, 1991). The superoxide radical is 
formed in almost all aerobic cells (Fridovich, 1986). Any living system producing super 
oxide is expected to produce H2O2 by chemical or enzymatic dismutation of O2'. 
Endogenously generated oxygen derived species may cause damage to biological 
molecules, including DNA, by a variety of mechanisms (Halliwell and Arouma, 1991). 
Much of the toxicity of O2" and H2O2 is thought to resuU from their metal ion-catalyzed 
conversion into highly reactive 'OH (Halliwell and Gutteridge, 1989; Halliwell and 
Aruoma; 1991), The hydroxyl radical produces a unique and extensive pattern of 
chemical modifications in DNA and nucleoprotein, including modified bases and DNA 
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protein crosslinks (Oleinick etal., 1987; von Sonntag, 1987; Dizdaroglu, 1991; Halliwell 
and Aruoma, 1991). Such DNA lesions may be promutagenic and may play a role in 
carcinogenesis (Halliwell and Gutteridge, 1989; Halliwell and Aruoma, 1991; Breimer, 
1990; Floyd, 1990). Evidence exist that DNA damage by endogenous free radicals occurs 
and accimiulates in vivo, and that there is a steady state level of fi«e radical modified 
bases in cellular DNA (Cathcart et al., 1984; Kasai et al., 1986; Adelman et al., 1988; 
Richter et al, 1988; Stillwell et al., 1989; Fraga et al., 1990; Fraga et al., 1991). 
Continuous endogenous damage to cellular DNA by free radicals and accumulation of 
such damage has been suggested to significantly contribute to carcinogenesis in humans 
(Totter, 1980; Ames, 1983; Ames, 1989). Because of their ability to damage DNA, free 
radicals are thought to be involved in all stages of carcinogenesis (Cerutti, 1985; 
Halliwell and Aruoma, 1991; Floyd, 1990). Evidence exists that tumor cells have 
abnormal levels and activities of antioxidant enzymes, such as superoxide dismutase or 
catalase leading to accumulation of O^ and H2O2 that induce damage to DNA (Olinski et 
al, 1992). 
Understanding the role of free radicals at the molecular level may lead to an 
understanding of cancer related to free radicals. Olinski et al in 1992, investigated 
endogenous levels of typical free radical modified pyrimidines and purines of DNA in 
chromatin sample isolated from various human cancerous tissues and their cancer-free 
surrounding tissues. In all tissue types examined, the endogenous amounts of most 
pyrimidine- and purine-derived DNA lesions in cancerous tissues were found to be 
consistently higher than in their respective cancer-free surrounding tissues. It is known 
that H2O2 treatment of mammalian cells causes formation of DNA lesions in their 
chromatin, most likely via site-specific *0H production (Dizdaroglu et al, 1991). 
Epidemiological studies involving measurement of typical free radical modified DNA 
bases in a large variety of individual tumor tissues and their respective normal tissues 
may provide insight into mechanisms of carcinogenesis related to oxygen-derived 
species. 
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Cancer: The chromatin connection 
For decades chromatin was considered to be an inert structure whose only role 
was the compacting and confining of DNA inside the eukaryotic nucleus. However, the 
tremendous progress in this field over the last 10 years has dramatically elevated 
chromatin to a key position in the control of gene activity. Its role in mediating the 
transformation of a normal cell into a malignant state is particularly interesting (Ballestar 
and Estellar, 2002). Cancer is a process driven by the accumulation of abnormalities in 
gene function. While many of these changes are genetic, epigenetically mediated changes 
or heritable changes in gene expression are being increasingly appreciated. Two key 
components of heritable changes that are closely tied to one another are formation of 
chromatin which modulates transcription and establishing patterns of DNA methylation 
(Rountreee/a/.,2001). 
The most significant aspect of the cancer-chromatin connection is the recognition 
that the expression of key genes required to convert a normal cell to a cancer cell relies 
an enzymes. By alternately acetylating or deacetylating histones in the context of ATP 
driven chromatin remodelling, the accessibility and transcriptional competence of a gene 
can be determined. Much of pathological gene silencing that occurs in cancer is a 
consequence of the mistargeting of these enzymes (Wolffe, 2001). 
DNA methylation involvement in cancer has become one of the hottest topics in 
cancer research. A major breakthrough in the field with in the last 5 years has been the 
recognition of the key role of chromatin as a mediator between DNA methylation and 
transcriptional silencing of genes relevant to cancer (Ballestar and Estellar, 2002). The 
disruption of normal methylation patterns, with both hypomethylation and 
hypermethylation events occurring is a hallmark of tumorigenesis (Baylin and Herman, 
2000; Robertson and Wolffe, 2000). A number of studies have shown that aberrant 
methylation is associated with changes in the chromatin structure, in particular, 
nucleosome position patterning (Hennig et al., 1995; Patel et al, 1997) and histone 
acetylation levels (Gilbert and Sharp, 1999; Torres et al., 2000). The understanding of the 
mechanism by which chromatin connects DNA methylation to gene silencing is 
fundamental to the design of drugs that specifically reactivate the silenced tumour 
suppressor genes. (Ballestar and Estellar, 2002). 
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Objectives of the present study 
An increased production of oxygen derived species such as super oxide anion 
radical, singlet oxygen, hydroxyl radical, hydrogen peroxide etc within the cells 
frequently leads to DNA damage by a variety of mechanisms and such species have been 
implicated in the etiology of many human diseases including SLE and cancer. The 
complex and non-organ specific nature of SLE has made it difficult for researchers to 
unravel the genetic defects and pathogenic mechanisms underlying this disease. It is not 
clear whether some form of DNA, such as product of viral infection or a fragment of 
chromatin or chemically modified DNA serves as immunogen. 
In the present study, chromatin was isolated from goat liver. It was modified with 
hydroxyl radical fOH) generated by UV irradiation in presence of hydrogen peroxide and 
singlet oxygen-superoxide anion radical ('02-02~) generated by illumination of 
riboflavin. Native and modified chromatin were characterized by UV and 
fluorescence spectroscopy, thermal denaturation studies and nuclease SI digestibility. 
Antigenicity of native and modified chromatin was probed by inducing antibodies 
in rabbits. Both the native and modified chromatin induced high titer antibodies. 
However *OH-chromatin and '02-02~-chromatin were found to be more immvuiogenic in 
comparison to native chromatin as assessed by direct binding ELISA. The specificity of 
induced antibodies was evaluated by competition ELISA and gel retardation assay. 
In order to assess the possible role of modified epitopes in the etiology of diseases 
such as SLE and cancer, sera from SLE and cancer patients were investigated for the 
presence of antibodies to native and modified chromatin. 
a:^^^€4^^rg^^/^^^2^ 
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MATERIALS 
Calf thymus DNA, nuclease SI, riboflavin, superoxide dismutase, DNase 1 
(RNase free), bovine serum albumin, anti-human/anti-rabbit IgG-alkaline phosphatase 
conjugate, p-nitrophenyl phosphate, ethidium bromide, Coomassie Brilliant Blue G-250 
and R-250, sodium dodecyl sulphate, Tween-20, Triton X-100, Millipore filter (0.45 nm 
pore size), Freund's complete and incomplete adjuvants, polydeoxyribonucleotides, and 
agarose were purchased from Sigma Chemical Company, U.S.A. Synthetic 
polynucleotides, Ficoll 400, xylene cyanole FF were purchased from Pharmacia Fine 
Chemicals, Sweden. Folin-Ciocalteau reagent and Blue Dextran 2000 were purchased 
from Centre for Biochemical Technology, New Delhi. Protein A sepharose CL 4B was 
from Genei, India. Absolute ethanol was obtained from BDH Laboratory Supplies, 
England. Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm 
diameter) were purchased from NUNC, Denmark. Acrylamide, ammonium persulphate, 
biascrylamide, N, N, N', N'-tetramethylethylenediamine (TEMED) were from Bio-Rad 
Laboratory U.S.A. EDTA (disodium salt), hydrogen peroxide, sucrose, chloroform, 
isoamyl alcohol, methanol, glacial acetic acid were from Qualigens, India. 
Diphenylamine was chemically pure. All other reagents/chemicals were of the highest 
analytical grade available. 
Equipments 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer and 
controller unit, high speed tissue homogenizer (York Scientific industries, Delhi), ELISA 
microplate reader MR-600 (Dynatech, U.S.A.), ELICO pH meter model LI-120, 
ultraviolet lamp (Vilber Lourmat, France), UV-transilluminator (Vilber Lourmat, 
France), agarose gel elecfrophoresis assembly (GNA-100) and gradient mixer GM-1 
(Pharmacia, Sweden), Avanti 30 table top high speed refrigerated centrifiige (Beckman, 
U.S.A.), polyacrylamide gel electrophoresis assembly (Bio-Rad, U.S.A.), fluorimeter 
(Hitachi, Japan) were the major equipments used in this study. 
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Collection of Sera and Blood Samples 
Normal human sera were obtained from healthy subjects. SLE sera were obtained 
from outdoor and indoor patients of the Department of Medicine, All India Institute of 
Medical Sciences, New Delhi. The SLE sera showed high titre anti-DNA antibodies and 
fulfilled the American College of Rheumatology revised criteria for the classification of 
SLE(Amettefa/., 1988). 
M E T H O D S 
Determination of DNA concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2g) was dissolved in 200 ml boiling hexane. After adding 0.5 g 
of activated charcoal, the hot mixture was filtered through Whatman No. 1 filter paper 
and the filterate was kept overnight at 4°C and dried at room temperature before use. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic 
acid and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and 
incubated at 70"'C for 15 min. 100 )il of 5.43 mM acetaldehyde was added followed by 
2.0 ml of freshly prepared diphenylamine reagent. The contents were mixed and 
incubated at room temperature for 16-20 hrs. Absorbance was read at 600 nm and the 
concentration of DNA in unknown samples was determined from a standard plot of calf 
thymus DNA purified free of RNA and proteins. 
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Determination of protein concentration 
Protein was estimated by the methods of Lowry e/ a/ (1951) and Bradford (1976). 
Protein estimation by Folin's-plienol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), Cu^ "^  
ions (to chelate proteins) and tartarate (to keep the Cu^ ^ ions in solution at high pH). 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New Delhi 
and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) 2 percent sodium carbonate in 100 mM sodium hydroxide, 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) and 
(ii) in the ratio of 50:1. 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. 1 ml of working Folin-Ciocalteau reagent was 
added and the tubes were read at 660 nm after 30 min. The concentration of protein in 
unknown sample was determined from a standard plot of bovine serum albumin. 
Protein estimation by dye-binding metliod 
This assay is based on color change when Coomassie Brilliant Blue G 250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color is observed (XTOax-595 nm). 
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(a) Dye preparation 
100 mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution was 
diluted to a final volume of 1 litre and filtered through Whatman No. 1 filter paper to 
remove undissolved particles. 
(b) Protein assay 
To 1 ml of solutions containing 10-100 ^g protein was added 5 ml of dye solution 
and contents mixed by vortexing. The absorbance was read at 595 nm after 5 min against 
a reagent blank. 
Purification of calf thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and single 
stranded regions as described by AH et al. (1985). DNA (2 mg/ml) was dissolved in 
0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and 
extracted with an equal volume of chloroform isoamyl alcohol (24:1) in a stoppered 
container for 1 hr. The aqueous layer containing DNA was separated from the organic 
layer and re-extracted with chloroform-isoamyl alcohol. The DNA was precipitated with 
two volume of cold absolute ethanol and collected on a glass rod. After drying in air, the 
DNA was dissolved in acetate buffer (30 mM sodium acetate containing 30 mM zinc 
chloride, pH 5.0) and treated with nuclease SI (150 units/mg DNA) at 37°C for 30 min to 
remove single stranded regions. The reaction was stopped by adding one-tenth volume of 
200 mM EDTA, pH 8.0. The nuclease SI treated DNA was extracted twice with 
chloroform isoamyl alcohol and finally precipitated with two volimies of cold ethanol. 
The precipitate was dissolved in phosphate-buffered saline (PBS) (10 mM sodium 
phosphate containing 150 mM sodium chloride), pH 7.4. 
Poly acrylamide gel electrophoresis (PAGE) for proteins 
PAGE was performed as described by Laemmli (1970). 
33 
(i) Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm bis-
acrylamide in distilled water to a final volume of 100 ml. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48.0 ml of IN 
HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 100 
ml with distilled water. 
(ill) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH titrated to 6.8 with 1N 
HCl and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and final volume made up to one litre. 
(v) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. The 
resolving gel mixture was prepared by mixing the components in the appropriate volume 
and poured into the space between the glass plates leaving sufficient space at the top for 
the stacking gel. After the polymerization of separating gel, stacking gel mixture was 
poured and allowed to solidify. Protein samples containing 10% glycerol and 0.002% 
bromophenol blue were applied and electrophoresis was carried out at 60V for 6-8 hrs. 
Staining of the gel was achieved with 0.1% Coomassie Brilliant Blue R 250 (in 25% iso-
propanol and 10% glacial acetic acid). Destaining was carried out in a mixture of 10% 
acetic acid and 10% methanol. 
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Recipe for 7.5% SDS-PAGE 
Solutions 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10% SDS 
1.5% ammonium persulpahte 
TEMED 
Stacking gel 
1.25 ml 
2.5 ml 
-
5.65 ml 
0.1ml 
0.5 ml 
0.75 fil 
Resolving gel 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15^1 
Isolation of chromatin 
Chromatin was isolated as described by Bonner et al (196© with slight 
modifications. 10 g of fresh goat liver was homogenized with 200 ml of saline EDTA 
(0.075 M NaCl, and 0.024 M EDTA, pH 8.0). The homogenate was strained through 6-8 
layers of cheesecloth. The filtrate was centrifuged at 1500 g for 15 minutes. The pellet 
was homogenized in 40 ml of Tris buffer, and then sedimented at 10,000 g for 15 
minutes. This step was repeated once. The final pellet was suspended in 30 ml of Tris 
buffer (0.05 M, pH 8.0). Five-milliliter aliquots of the above suspension were layered on 
25 ml portions of 1.7 M sucrose (0.01 M Tris buffer, pH 8.0) contained in centrifuge 
tubes. The upper two-thirds of each tube were gently mixed and the tubes were then 
centrifuged at 21,000 rpm for 3 hours in F0650 rotor (rotor temperature 4°C). The pellets 
were resuspended in 0.01 M Tris buffer, pH 8.0, and dialyzed against the same buffer 
overnight. The dialyzed suspension was sheared in Virtis homogenizer for 90 seconds, 
stirred for 30 minutes, and then centrifuged at 10,000 g for 30 minutes. The supernatant 
was taken out and UV spectra of the diluted supernatant was recorded. The supernatant is 
referred to as sheared liver chromatin. 
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Modification of chromatin by hydroxyl radical 
Aqueous solution of chromatin in PBS, pH 7,4 was irradiated under 254 nm light 
for one hour at room temperature in the presence of hydrogen peroxide (15.1 mM). 
Excess of hydrogen peroxide was removed by extensive dialysis against PBS, pH 7.4. 
Modification of chromatin by superoxide anion radical and singlet 
oxygen 
Superoxide radical was detected by photosensitized reduction of nitroblue 
tetrazolium (NBT), leading to the formation of a blue coloured products, nitroblue 
formazan (Nakayama et al, 1983). Production of superoxide radical was confirmed by 
monitoring the inhibition of formation of blue coloured product in the presence of 
superoxide dismutase (SOD), 
Formation of singlet oxygen was measured in aqueous solution by monitoring, the 
bleaching of p-nitrosodimethylaniline (pRNO) (Kraljic and Moshni, 1978). Production of 
singlet oxygen was confirmed by monitoring the bleaching of pRNO in presence of 
sodium azide (NaNs), a specific quencher of singlet oxygen. 
Isolated chromatin was modified by the method of Naseem et al (1988). A total 
volume of 3,0 ml of reaction mixture contained chromatin, A26o=2, 50 mM potassium 
phosphate buffer, pH 7,8, 1,1 mM EDTA, 0.06% Triton X-100 and 40 i^M riboflavin. 
The reaction mixture was irradiated at 365 nm at room temperature followed by extensive 
dialysis to remove riboflavin and Triton X-100. 
Spectroscopic analysis 
The ultraviolet spectra of modified and unmodified chromatin samples were 
recorded in the wavelength range of 230-400 nm on a Shimadzu UV-240 
spectrophotometer. The modifications incurred on native chromatin were also analyzed 
by UV-difference spectroscopy. 
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Fluorescence emission spectroscopy of native and modified chromatin samples 
using ethidium bromide was also performed. 
Absorption-temperature scan 
Thermal denaturation analysis of chromatin was performed in order to ascertain 
the degree of modification incurred on the chromatin by determining mid point melting 
temperature (Tm). Native and modified chromatin samples were subjected to heat 
denaturation on a Shimadzu UV-240 spectrophotometer coupled with a temperature 
programmer and controller assembly (Hasan and Ali, 1990). All the samples were melted 
from 30°C to 95''C at a rate of 1.5°C / min after 10 min equilibration at 30°C. The change 
in absorbance at 260 nm was recorded with increasing temperature. Percent denaturation 
was calculated as follows: 
A - A Percent denaturation = — ^ x 100 
Where, AT = Absorbance at a temperature T°C. 
Amax = Final maximum absorbance on the completion of 
denaturation (95°C). 
A30 = Initial absorbance at SO^ 'C. 
Nuclease SI digestibility 
Native and modified chromatin were characterized by nuclease SI digestibility 
(Matsuo and Ross, 1987). One microgram each of native and modified chromatin in 
acetate buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated 
with nuclease SI (20 units/^ ig DNA) for 30 min at 37°C, The reaction was stopped by 
adding one tenth volume of 200 mM EDTA, pH 8.0. The digested and control samples 
were subjected to agarose gel electrophoresis. 
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(i) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50°C and then 
poured into gel tray and allowed to solidify at room temperature. 
(ii) Sample preparation and loading 
Native and modified chromatin samples treated with nuclease SI were mixed with 
one-tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA in lOX electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide (0.5 
Hg/ml), viewed by illumination under UV light and photographed. 
Immunization schedule 
Native and modified chromatin (50 fig) were emulsified with an equal volume of 
complete Freund's adjuvant and injected intramuscularly in female rabbits. Subsequent 
injections were given in incomplete Freund's adjuvant. Each animal received a total of 
300 i^g of antigen in the course of 6 injections. Blood was collected from marginal vein 
of the ear. Serum was separated and decomplemented by heating at 56°C for 30 minutes. 
Pre-immune serum was collected prior to immunization. The sera were stored in small 
aliquots at -20°C with 0.1% sodium azide as preservative. 
Isolation of IgG by Protein-A agarose 
Serum IgG was isolated by affinity chromatography on Protein A-agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to column 
(12mm X 45mm) equilibrated with the same buffer. The wash through was recycled 2-3 
times. Unboimd IgG was removed by extensive washing with PBS, pH 7.4. The bound 
IgG was eluted with 0.58% acetic acid in 0,85% sodium chloride (Goding, 1976) and 
neutralized with 1 ml of IM Tris-HCl, pH 8.5. Three ml fractions were collected and read 
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at 251 and 278 nm. The IgG concentration was determined considering 1.40 OD280 = 1 0 
mg IgG/ml. The isolated IgG was then dialyzed against PBS, pH 7.4 and stored at -20°C 
with 0.1% sodium azide. 
Immunological detection of antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and gel 
retardation assay. 
(a) Enzyme linked immunosorbent assay 
The following reagents were prepared in distilled water and used in enzyme 
immunoassay. 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl, pH 7.4, containing 500 ^1 Tween 
20/L. 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 mM 
magnesitun chloride. 
Citrate-pliosphate buffer 
50 mM citric acid, 50 mM Na2HP04, pH 5.0. 
Substrates 
(i) 500 ng p-nitrophenyl phosphate (p-NPP)/ml of carbonate-bicarbonate 
bufifer. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as solid 
support. One hundred microlitre of 2.5 |ag/ml antigen in TBS, pH 7.4 was coated in test 
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wells of microtitre plates, incubated for 2 hr at ZVC and overnight at 4°C. The antigen 
coated wells were washed three times with TBS-T to remove imbound antigen. 
Unoccupied sites were blocked with 150^1 of 1.5% BSA in TBS for 4 - 5 hrs at room 
temperature. The plates were washed once with TBS-T and antibody (100 jil/well) to be 
tested, were diluted in TBS and added to each well. After 2 hr incubation at 37°C and 
overnight at 4*'C, the plates were washed four times with TBS-T and an appropriate anti-
immunoglobulin alkaline phosphatase conjugate was added to each well. After incubation 
at 37°C for 2 hr, the plates were washed four times with TBS-T and three times with 
distilled water and developed using p-nitrophenyl phosphate substrate respectively. The 
absorbance was recorded at 410 nm on an automatic microplate reader. Each sample was 
run induplicate. The control wells were treated similarly but were devoid of antigen. 
Results were expressed as a mean of Atest - Acontroi-
(b) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition ELISA 
(Hasan et al, 1991). Varying amounts of inhibitors (0-20 ng/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature for 
2 hr and overnight at 4''C. The immune complex thus formed was coated in the wells 
instead of the serum. The remaining steps were the same as in direct binding ELISA. 
Percent inhibition was calculated using the formula 
Percent inhibition = 1 «^^«^L. x 100 
A 
uninhibited 
(c) Band shift assay 
For the visual detection of antigen antibody binding and immune complex 
formation, gel retardation assay was performed (Sanford et al, 1988), A constant amount 
of antigen (native and modified chromatin) was incubated with varying amounts of IgG 
in PBS, pH 7.4 for 2 hr at 37°C and overnight at 4°C. One-tenth volume of 'stop mix' 
dye was added to the mixture and electrophoresed on 1% agarose for 2 hr at 30 mA in 
TAE buffer, pH 7.9. The gels were stained with ethidium bromide (O.S i^g/ml), visualized 
under UV light and photographed. 
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UV absorption spectrum of isolated chromatin 
The isolated goat liver chromatin exhibited major peak at 260 mn and showed 
negligible absorbance at around 320 nm (Fig. 1). A25g/A28o ratio was around 1.63 and 
A258/A320 was aroimd 9. 
Gel electrophoresis pattern of chromatin 
Agarose gel electrophoresis of isolated chromatin was performed on 1% agarose 
gel (Fig. 2). The purified chromatin migrated as a single homogenous electrophoretic 
band. 
Photochemical generation of superoxide anion radical and singlet 
oxygen 
Superoxide anion radicals (OD and singlet oxygen ('O2) were generated by 
illumination of riboflavin with UV light (365 nm). The generation of superoxide anion 
radicals was observed by reduction of nitroblue tetrazolium (NBT) (Fig. 3) and 
generation of singlet oxygen was observed by bleaching of pRNO (Fig. 4). The 
generation of these radicals was further confirmed by the use of their respective 
quenchers i.e. SOD for superoxide anion radical and sodium azide for singlet oxygen. 
Evidence for the formation of 'O2 was obtained by examining the progress of the reaction 
in presence of various concentrations of sodium azide (NaNa), a specific quencher for 
*02. A near complete inhibition of 'O2 production was observed at 100 mM NaNs 
(Fig. 5). Superoxide dismutase was used to confirm the production of 02~, however no 
inhibition in the formation of blue coloured product (nitroblue formazan) was observed 
due to the presence of 'O2 in the system (Fig. 6). Inhibition in the formation of nitroblue 
formazan was observed when both SOD and NaNs, specific quencher for 'O2 were used 
(Fig. 7). 
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Fig. 1. UV absorption spectrum of liver chromatin. 
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Fig. 2. Agarose gel electrophoresis pattern of chromatin. 
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Fig. 3. Time dependent generation of superoxide (O2 ) anion radical by riboflavin in 
light (A), in dark (•), without Triton X-100 (O), without riboflavin (A). 
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Fig. 4. Time dependent production of singlet oxygen ('O2) by riboflavin in light (O), 
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Fig.' 6. Quenching of O2 with increasing concentrations of SOD. 
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Modification of cliromatin by superoxide anion radical and singlet 
oxygen 
Isolated chromatin was modified by the method of Naseem et al. (1988). A total 
volume of 3.0 ml of reaction mixture contained chromatin, A260=2, 50 mM potassium 
phosphate buffer, pH 7.8, 1.1 mM EDTA, 0.06% Triton X-100 an 40 i^M riboflavin. The 
reaction mixture was irradiated at 365 nm at room temperature followed by extensive 
dialysis to remove riboflavin and Triton X-100. 
Modification of chromatin by hydroxyl radical 
Goat liver chromatin was modified with hydroxyl radical ('OH) generated by UV 
irradiation at 254 nm in presence of hydrogen peroxide. The modified samples were 
dialyzed extensively against 0.01 M Tris, pH 8 to remove excess hydrogen peroxide. 
Spectroscopic analysis of modified chromatin 
Ultraviolet absorption spectral studies 
i • -
The UV absorption spectra of O2- 02-modified chromatin showed peak shift and 
hyperchromicity at 260 nm. The percent hyperchromicity was 46% and peak shift was 12 
nm towards longer wavelength (Fig. 8). The modifications incurred on chromatin were 
also analyzed by UV-difference spectroscopy (Fig. 8, inset). The spectral curve exhibited 
increased absorbance at around 275 nm. A shoulder was also observed at around 282 nm. 
Chromatin was modified in the absence and presence of sodium azide. Figure 9 
shows the UV absorption spectra of native chromatin, O2 - d2-chromatin and "02 - O2-
chromatin in the presence of sodium azide (100 mM). Damage obtained in the absence of 
sodium azide was to a greater extent as compared to the damage in its presence. 
The UV absorption spectra of 'OH-modified chromatin showed a decrease in 
absorbance over the entire UV range, with a hypochromicity of 20% at 260 nm (Fig. 10). 
UV-difference spectra of *OH-chromatin with reference to native chromatin exhibited 
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Fig. 8. UV absorption spectra of native chromatin (—) and '02-02~-chromatin (—). 
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Fig. 9. UV absorption spectra of chromatin modified in presence of 100 mM sodium 
azide, a specific quencher of 'O2. Native-chromatin (~), '02-0*2"- modified-
chromatin (-—), 02-02~-modified-chromatin in presence of sodium azide (—). 
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Fig. 10. UV absorption spectra of native chromatin (—) and 'OH-chromatin (—). 
Inset: UV difference spectra of *OH-chromatin (—). Native chromatin served 
as control. 
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negative peak between 260 nm to 270 nm and increased absorbance at around 300 nm 
(Fig. 10, inset). 
Generation of* OH radical was confirmed using mannitol as a specific quencher of 
'OH radical. 400 bp native calf thymus DNA was modified in absence and in the presence 
of two different concentrations of mannitol (75 mM and 150 mM). The data showed a 
marked hypochromicity of DNA sample in the absence of mannitol. Whereas lesser 
hypochromicity was observed in presence of mannitol (Fig. 11). 
Chromatin was modified in the absence and presence of mannitol. Figure 12 
shows UV absorption spectra of native chromatin, 'OH-chromatin and "OH-chromatin in 
the presence of 150 mM mannitol. Damage in the absence of mannitol was appreciable 
whereas much less damage was observed in the presence of mannitol. 
Fluorescence spectroscopy 
Fluorescence spectra of native and O2 - Oa-chromatin was taken using ethidium 
bromide (Fig. 13). A decrease in the fluorescence intensity was seen in case of O2 - O2-
chromatin as compared to its native form. Destruction of the structure of chromatin and 
strand breaks due to modification by 0*2~ and 'O2 may attribute to the decrease in 
fluorescence intensity. 
Fluorescence spectra of *OH-chromatin also showed a decrease in the 
fluorescence intensity as compared to native chromatin probably indicating the 
generation of strand breaks and alteration in the structure of chromatin (Fig. 14). 
Nuclease SI digestibility of native and modified cliromatin 
Native and modified chromatin were digested with nuclease SI (20 units/jig 
chromatin) for 30 minutes at 37°C, undigested chromatin sample served as control. 
Samples were run on 1% agarose gel. Figure 15 shows nuclease SI digestibility of native 
and O2- 02-chromatin and Figure 16 shows nuclease SI digestibility of native and 'OH-
chromatin. The results showed substantially decreased intensity in case of both of the 
modified samples. However, the intensity loss in case of unmodified chromatin was less 
as compared to modified samples. 
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Fig. 11. UV absorption spectra of 400 bp calf thymus DNA modified by hydroxy! 
radical in absence and presence of two concentrations of mannitol. Native 400 
bp DNA (—), 'OH- modified 400 bp DNA (•--), 'OH-modified 400 bp DNA 
with 75 mM mannitol ( ) and 'OH-modified 400 bp DNA with 150 mM 
mannitol (—•). 
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Fig. 12. UV absorption spectra of chromatin modified by hydroxyl radical in absence 
and presence of mannitol, a specific quencher of hydroxyl radical. Native 
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Fig. 15. Nuclease SI digestibility of native and 'O2-O2 -chromatin. Lane 1 contained 
native chromatin, while lane 2 contained native-chromatin treated with 
nuclease SI. Lane 3 contained 'Oa-O'a'-chromatin, while lane 4 contained 'O2-
O2 -chromatin treated with nuclease SI for 30 min. Electrophoresis was 
carried out on 1% agarose gel for 2 hrs at 30 mA. 
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Fig. 16. Nuclease SI digestibility of native and *OH-chromatin. Lane 1 contained 
native chromatin, while lane 2 contained native-chromatin treated with 
nuclease SI. Lane 3 contained *OH-chromatin, while lane 4 contained 'OH-
chromatin treated with nuclease SI for 30 min. Electrophoresis was carried out 
on 1% agarose gel for 2 hrs at 30 mA. 
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Thermal denaturation of native and modified cliromatin 
Thermally induced transitions were measured spectrophotometrically at 260 nm 
by heating samples at a rate of 1-5°C per min. Melting curves were recorded at 
temperatures from SO^ C to 95°C. Increase in absorption at 260 nm was taken as a measure 
of denaturation. Figure 17 shows thermal denaturation profile of native and O2 —O2-
chromatin. The melting temperature of native chromatin at which 50% of the structural 
organisation is lost was found to be 83°C, while in case of O2 - Oa-modified chromatin it 
was found to be 78°C, a net decrease of 5°C in the Tm value of modified chromatin was 
observed when compared to its unmodified native conformer. 
Figure 18 shows thermal denaturation profile of native and 'OH-modified 
chromatin. In case of *OH-chromatin Tm was found to be 74°C, a net decrease of 9°C in 
the Tm value of 'OH-chromatin was observed when compared to native chromatin. These 
findings indicate that the decrease in Tm is primarily due to structural alterations of 
chromatin. Thermal denaturation characteristics of native, O2- 02-chromatin and 'OH-
chromatin are summarized in Table 3. 
Antigenicity of native and modified cliromatin 
The antigenicity of native and modified chromatin was determined by inducing 
antibodies in rabbits against native chromatin, O2- 02-chromatin and 'OH-chromatin. 
The antigenic specificity of induced antibodies was assayed by direct binding and 
competition ELISA. The binding of immune IgG to the respective immunogen and native 
chromatin was also probed by band shift assay. 
(a) Antibodies against native chromatin 
The antiserum showed a titre of at least 1:1600 when tested by direct binding 
ELISA (Fig. 19). Preimmune serum showed negligible binding. Induced antibodies were 
found to be specific for the immunogen. Inhibition ELISA showed a maximum of 61% 
inhibition (Fig. 20). Fifty percent inhibition was achieved v^th 16.4 |xg/ml of native 
chromatin. 
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Fig. 17. Thermal denaturation profile of native (O) and 'O2-O2 -chromatin (•). 
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Fig. 18. Thermal denaturation profile of native (O) and "OH-chromatin (•). 
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TABLE -3 
Thermal denaturation characteristics of native chromatin/Oj - O2-
chromatinand * OH-chromatin 
Parameter Native chromatin 'O2 - 02-chromatiii *OH-chromatin 
Percent hyperchromicity 43.1 17.4 20 
at 95°C 
Melting temperature 83 78 74 
(Tm, °C) 
Onset of melting °C 50 40 35 
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Fig. 19. Direct binding ELISA of native chromatin with preimmnne (A) and immune 
sera (A). Microtitre plates were coated with native chromatin (2.5 ^ g/ml). 
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(b) Antibodies against Oj - OVchromatin 
*02 - oVchromatin was highly immunogenic in rabbits. The antiserum showed a 
high titre of at least 1:12800 when tested by direct binding ELISA (Fig. 21). Pre-immune 
serum served as negative control, did not show any appreciable binding to O2 - O2-
chromatin. The specificity of anti- O2 - 02-chromatin antibodies was evaluated by 
competition ELISA. A maximum of 70% inhibition in antibody activity was obtained at 
an immunogen concentration of 20 ng/ml. The concentration of immunogen required for 
50% inhibition was 14.3 ng/ml (Fig. 22). 
(c) Antibodies against *OH -chromatin 
The antiserum showed a high titre of 1:12800 by direct binding ELISA. The 
binding of pre-immune serum was of low magnitude (Fig. 23). In competition ELISA, a 
maximum of 77% inhibition was observed at 20 i^g/ml and 50% inhibition was achieved 
at 12.9 ng/ml of immunogen (Fig. 24). 
Puriflcation and characterization of immune IgG 
Immunoglobulin G was isolated fi"om pre-immune and immune rabbit serum by 
affinity chromatography on Protein A Sepharose CL-4B column (Figs. 25, 28, 31). The 
purity of IgG was evaluated by SDS-polyacrylamide gel electrophoresis in absence of a 
reducing agent. The purified IgG migrated as a single band upon electrophoresis (Figs. 
25,28,31 inset). 
Direct binding ELISA of the purified IgGs exhibited strong binding to the 
respective inmnmogens (Figs. 26, 29, 32). Pre-immune IgGs as negative control showed 
negligible binding. The specificity of purified IgG was evaluated by competitive 
inhibition assays. 
Band shift assay 
The binding of native, O2- 02-chromatin and *OH-chromatin to their immune 
IgG was fiirther ascertained by band shift assay. Constant amounts of native and modified 
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Fig. 21. Direct binding ELISA of 'O2-O2 -chromatin with preimmune (A) and immune 
sera (A). Microtitre plates were coated with '02-02~-chromatin (2.5 fj.g/ml). 
67 
Z 
o 
h i 
z 
H 
Z 
UJ 
o 
X 
Ui 
Q. 
20 
40 -
60 
80 
100 
0.01 0.1 10 100 
INHIBITOR CONCENTRATION (ug/ml) 
Fig. 22. Inhibition ELISA of anti-'Oi-Or-chromatin immune (A) and pre-immune (A) 
sera with 'Oi-Oi"-chromatin. Microtitre plates were coated with 'O2- 0*2-
chromatin (2.5 |ag/ml). 
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Fig. 23. Direct binding ELISA of "OH-chromatin with preimmune (A) and immune 
sera (A). Microtitre plates were coated with *OH-chromatin (2.5 ng/ml). 
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Fig. 24. Inhibition ELISA of anti-'OH-chromatin immune (A) and pre-immune (A) 
sera with *OH-chromatin. Microtitre plates were coated with 'OH-chromatin 
(2.5 ^ ig/ml). 
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Fig. 25. Elution profile of anti-native chromatin IgG on Protein-A Sepharose CL-4B 
affinity column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide 
gel. 
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chromatin were incubated with varying amounts of respective immune and pre-immune 
IgG for 2 hrs at room temperature and overnight at 4°C. The immune complex were then 
electrophoresed on 1% agarose for 2 hr at 30 mA. Figure 27 shows the formation of 
complexes between native chromatin and anti-native chromatin IgG. With increasing 
concentration of IgG, the formation of high molecular weight immune complexes 
mcreased as judged by their fluorescence intensity, whereas, the amoimt of unbound 
chromatin showed a proportional decrease in intensity. No appreciable change was 
observed with pre-immune IgG. Figure 30 shows the formation of immune complexes 
between anti-'Oi - oV-chromatin IgG and immunogen and Figure 33 shows the formation 
of complexes between 'OH-chromatin and anti-'OH-chromatin IgG. Preimmune IgGs 
showed negligible binding. 
Immuno-crossreactivity of anti-native chromatin antibodies 
Figures 34, 35 show the inhibition of anti-native chromatin antibodies binding to 
native chromatin using various inhibitors. A maximum of 68% inhibition of anti-native 
chromatin antibody with immunogen as inhibitor was observed. Fifty percent inhibition 
was achieved with only 14.7 |xg/ml of native chromatin. DNAse I digested chromatin at a 
concentration of 20 i^g/ml exhibited 37% inhibition of binding of immune IgG to native 
chromatin. O2- 02-chromatin and *OH-chromatin showed inhibitions of 29% and 31% 
(Fig. 34 a). Calf thymus DNA,'02- OV-DNA, 'OH-DNA showed inhibitions of 20%, 
11% and 8% respectively (Fig. 34 b). Synthetic polynucleotides such as poly(dA-
dT).poly(dA-dT), poly(dA-dU).poly(dA-dU) and poly(dI-dC).poly(dI-dC) showed lower 
inhibitions of 10%,7.5% and 5% respectively at 20 fig/ml inhibitor concentration (Fig. 
35a). Chondroitin sulphate and cardiolipin at 20ng/ml showed 11% and 2% inhibition 
respectively (Fig. 35b), 
Immuno-crossreactivity of anti-Op-'O: chromatin antibodies 
Figures 36, 37 show inhibition studies of anti-02 - oVchromatin antibodies with 
various inhibitors. A maximum of 75% inhibition in the binding of anti-02 - 0*2-
chromatin with immunogen as inhibitor was observed. Fifty percent inliibition was 
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Fig. 26. Binding of affinity purified anti-native chromatin immune IgG (A) and 
preimmime IgG (A) to native chromatin. Microtitre plates were coated with 
native chromatin (2.5 |ig/ml). 
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Fig. 27. Band shift assay of (a) preimmune and (b) immune anti-native chromatin IgG 
binding to native chromatin. Native chromatin (2 ^g) was incubated with 
buffer (lane 1) and 20,30,40 and 50 |ag IgG through lanes 2 to 5, respectively 
for 2 hr at 37°C and overnight at 4°C. Electrophoresis was carried out on 1% 
agarose gel for 2 hr at 30 mA. 
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Fig. 28. Elution profile of anti-'02-02"-chromatin IgG on Protein-A Sepharose CL-4B 
affinity column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide 
gel. 
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Fig. 29. Binding of affinity purified anti-'02-Or-chromatin immune IgG (A) and 
preimmune IgG (A) to 'Oa-Or-chromatin. Microtitre plates were coated with 
'02-02~-chromatin (2.5 |ig/ml). 
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Fig. 30. Band shift assay of (a) preimmune and (b) immune anti-'02-02~-chromatin 
IgG binding to 'Oa-Or-chromatin. '02-02~-chromatin (2 ^g) was incubated 
with buffer (lane 1) and 20,30,40 and 50 |ig IgG through lanes 2 to 5, 
respectively for 2 hr at 37°C and overnight at 4°C. Electrophoresis was carried 
out on 1% agarose gel for 2 hr at 30 mA. 
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Fig. 31. Elution profile of anti-'OH-chromatin IgG on Protein-A Sepharose CL-4B 
affinity column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide 
gel. 
78 
E 
c 
< 
U 
O 
z 
< 
tc 
o 
ffl 
< 
0.70 
0.56 -
0.42 
0.28 
0.14 
0.00 
10 15 20 25 
IgG CONCENTRATION (ug/ml) 
Fig. 32. Binding of affinity purified anti-'OH-chromatin immune IgG (A) and 
preimmune IgG (A) to *OH-chromatin. Microtitre plates were coated with 
'OH-chromatin (2.5 |ig/ml). 
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Fig. 33, B^nd shift assay of (a) preimmune and (b) immune anti-'OH-chromatin IgG 
binding to 'OH-chromatin. *OH-chromatin (2 |ig) was incubated with buffer 
(lane 1) and 20, 40 and 50 )j,g IgG through lanes 2 to 4, respectively for 2 hr at 
37°C and overnight at 4°C. Electrophoresis was carried out on 1% agarose gel 
for 2 hr at 30 mA. 
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Fig. 34. Inhibition of anti-native chromatin IgG binding to native chromatin. 
Microtitre plates were coated with native chromatin (2.5 |J.g/mI). The 
competitors were (a) native chromatin (A), DNase I digested native chromatin 
(A), 'OH-chromatin (O), 'Oa-Or-chromatin (•) and (b) native calf thymus 
DNA (A), 'OH-DNA (A), '02-0r-DNA (O). 
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Fig. 35. Inhibition of anti-native chromatin IgG binding to native chromatin. Microtitre 
plates were coated with native chromatin (2.5 )ig/ml). The competitors were 
(a) poly(dA-dT).poly(dA-dT) (A), poly(dA-dU).poly(dA-dU) (A), poly(dI-
dC).poly(dl-dC) (O) and (b) chondroitin sulphate (A), cardiolipin (A). 
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TABLE - 4 
Antigenic specificity of anti-native chromatin antibodies 
Inhibitor Maximum % inhibition at 20 ^ ig/ml 
Native chromatin 68.0 
DNase I digested chromatin 37.0 
*OH-chromatin 29.0 
'O2 - oV-chromatin 31.0 
Native calf thymus DNA 20.0 
'OH-DNA 11.0 
'Oa-OV-DNA 8.0 
Poly(dA-dT).poly(dA-dT) 10.0 
Poly(dA-dU).poly(dA-dU) 7.5 
Poly(dI-dC).poly(dI-dC) 5.0 
Chondroitin sulphate 11.0 
Cardiolipin 2.0 
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achieved at 13.3 i^g/ml of'Oj - 02"-chromatin. Native chromatin showed an inhibition of 
around 35% at 20ng/ml. DNase I digested chromatin exhibited 36% inhibition of binding 
of immune IgG to 'O2 - oV-chromatin, 'OH-chromatin showed inhibition of 57% (Fig. 
36a). Calf thymus DNA,'O2 - OV-DNA and "OH-DNA showed inhibitions of 9%, 15% 
and 13.5 % respectively (Fig. 36b). Synthetic polynucleotides such as poly(dA-
dT).poly(dA-dT), poly(dA-dU).poly(dA-dU) and poly(dI-dC).poly(dI-dC) showed lower 
inhibitions of 12%, 6% and 9.2% respectively at 20 ^g/mi inhibitor concentration (Fig. 
37a). Chondriotin sulphate and cardiolipin at 20^g/ml showed 14% and 7% inhibition 
respectively (Fig. 37b). 
Immuno-crossreactivity of anti-*OH chromatin antibodies 
Figures 38, 39 show inhibition studies of anti-*OH chromatin antibodies with 
various inhibitors. A maximum of 85% inhibition in the binding of anti-'OH chromatin 
with immunogen as inhibitor was observed, concentration of immunogen required for 
fifty percent inhibition was only 11.8 |xg/ml. Native chromatin showed an inhibition of 
around 33% at 20^g/ml. DNase I digested chromatin exhibited 39% inhibition of binding 
of immune IgG to *OH-chromatin.'O2 - 02-chromatin showed inhibition of 61% (Fig. 
38a). Calf thymus DNA,'02 - 0*J-DNA and 'OH-DNA showed inhibitions of 12, 14.3 and 
18% respectively (Fig. 38b). Synthetic polynucleotides such as poly(dA-dT).poly(dA-
dT), poly(dA-dU).poly(dA-dU) and poly(dI-dC).poly(dI-dC) showed lower inhibitions of 
8%, 3% and 7% respectively at 20 i^g/ml inhibitor concentration (Fig. 39a). Chondroitin 
sulphate and cardiolipin at 20^g/ml showed 18% and 5% inhibition respectively (Fig. 
39b). Tables 4, 5 and 6 summarize the results of the inhibition studies of anti-native 
chromatin, anti-02 - 02-chromatin and anti-'OH-chromatin antibodies with various 
inhibitors. 
Reactivity of SLE sera with native and modified chromatin 
Sera from twenty four patients with systemic lupus erythematosus were tested for 
binding to native chromatin,'O2 - oVchromatin and "OH-chromatin. The binding pattern 
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Fig. 36. Inhibition ofanti-'02-02~-chromatin IgG binding to 'O2-O2"-
chromatin. Microtitre plates were coated with '02-Or-chromatin (2.5 \ig/m\). 
The competitors were (a) native chromatin (A), DNase I digested 02-0*2-
chromatin (A), *OH-chromatin (O), '02-Or-chromatin (•) and (b) native calf 
thymus DNA (A), 'OH-DNA (A), 'O2-OV-DNA (o). 
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Fig. 37. Inhibition of anti-'02-0*2"-chromatin IgG binding to 'Oi-Or-chromatin. 
Microtitre plates were coated with 'Oa-Or-chromatin (2.5 |ig/ml). The 
competitors were (a) poly(dA-dT).poly(dA-dT) (A), poly(dA-dU).poly(dA-dU) 
(A), poly(dI-dC).poly(dI-dC) (O) and (b) chondroitin sulphate (A), cardiolipin 
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TABLE - 5 
Antigenic specificity of anti-O^ - o'l-chromatin antibodies 
Inhibitor Maximum % inhibition at 20 jig/ml 
Native chromatin 35.0 
DNase I digested chromatin 36.0 
*OH-chromatin 57.0 
O2 - Oi-chromatin 75.0 
Native calf thymus DN A 9.0 
*OH-DNA 13.5 
'02-d2'-DNA 15.0 
Poly(dA-dT).poly(dA-dT) 12.0 
Poly(dA-dU).poly(dA-dU) 6.0 
Poly(dI-dC).poly(dI-dC) 9.2 
Chondroitin sulphate 14.0 
Cardiolipin 7.0 
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Fig. 38. Inhibition of anti-'OH-chromatin IgG binding to *OH-chromatin. Microtitre 
plates were coated with "OH-chromatin (2.5 i^g/ml). The competitors were (a) 
native chromatin (A), DNase I digested *OH-chromatin (A),'OH-
chromatin (O), *02-02~-chromatin (•) and (b) native calf thymus DNA (A), 
*OH-DNA (A), '02-0r-DNA (O). 
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Fig. 39. Inhibition of anti-*OH-chromatin IgG binding to 'OH-chromatin. Microtitre 
plates were coated with *OH-chromatin (2.5 |ig/ml). The competitors were (a) 
poly(dA-dT).poly(dA-dT) (A), poly(dA-dU).poly(dA-dU) (A), poly(dI-
dC).poly(dl-dC) (o) and (b) chondroitin sulphate (A), cardiolipin (A). 
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TABLE - 6 
Antigenic specificity of anti-'OH - chromatin antibodies 
Inhibitor Maximum % inhibition at 20 ng/ml 
Native chromatin 33.0 
DNase I digested chromatin 39.0 
'OH-chromatin 85.0 
*02 - dj-chromatin 61.0 
Native calf thymus DMA 12.0 
'OH-DNA 18.0 
'O2 - dz-DNA 14.3 
Poly(dA-dT).poly(dA-dT) 8.0 
Poly(dA-dU).poly(dA-dU) 3.0 
Poly(dI-dC).poly(dI-dC) 7.0 
Chondroitin sulphate 18.0 
Cardiolipin 5.0 
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of serum antibodies to native and modified chromatin was determined by direct binding 
ELISA. Nearly all the twenty four SLE sera showed stronger binding to 'O2 - OV 
chromatin and *OH-chromatin. No appreciable binding was observed with the sera of 
normal subjects (Figs. 40,41). 
The specificity of SLE sera for native and modified chromatin was evaluated by 
inhibition ELISA (Figs 42-53). Native chromatin showed maximum inhibitions ranging 
from 8% to 61% in twenty four SLE sera, 'O2- Oi-chromatin showed high percent 
inhibition ranging from 30% to 76%. Similarly 'OH-chromatin showed high percent 
inhibition ranging from 23% to 81%. Two sera showed low inhibitions. The inhibition 
data of native chromatin, O2 - 02-chromatin and OH-chromatin with SLE autoantibodies 
are summarized in Tables 7 and 8. 
Purification of SLE IgG 
SLE IgG was purified by affinity chromatography on Protein-A sepharose CL-4B 
column (Fig. 54) SDS-PAGE of purified IgG under non-reducing conditions showed a 
single homogenous band (Fig. 54, inset). 
Band shift assay 
Band shift assay was performed to confirm the interaction of native and modified 
chromatin with SLE autoantibodies. A constant amount of the antigen was incubated with 
increasing amounts of SLE IgG for 2 hr at 37°C and overnight at 4°C. These immune 
complexes were then electrophoresed on 1% agarose for 2 hr at 30 mA. Figure 55 shows 
the binding of SLE autoantibodies to native chromatin and'02- OV-chromatin, Figure 56 
shows the binding of SLE autoantibodies to native chromatin and *OH-chromatin. With 
increasing concentrations of IgG there is corresponding increase in the formation of high 
molecular weight immime complexes which resulted in retarded mobility and 
corresponding decrease in the fluorescence intensity of unbound antigen. 
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Fig. 40. Binding of 1:100 diluted SLE serum samples to native chromatin ( ^ ) , 'OH-
chromatin ( • • ) and '02-02~-chromatin ( M ) . Normal human sera (NHS) 
showed lower binding. Microtitre plates were coated with 2.5 |ig/ml of 
respective antigens. 
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Fig. 41. Binding of 1:100 diluted SLE serum samples to native chromatin ( ^ ) , 'OH-
chromatin ( 0 ) and '02-Or-chromatin ( ^ P ) . Normal human sera (NHS) 
showed lower binding. Microtitre plates were coated with 2.5 ng/ml of 
respective antigens. 
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Fig. 42. Inhibition of SLE autoantibodies binding by native and 'O2-O2 -chromatin. 
Microtitre plates were coated with '02-Or-chromatin (2.5ng/ml). (a) SLE sera 
1 and 2 by native chromatin (A,0) and 'Oa-Or-chromatin (A,»), (b) SLE sera 
3 and 4 by native chromatin (n,0) and '02-02~-chromatin (• ,•) . 
94 
z 
o 
h 
ffi 
z 
z 
H 
Z 
UJ 
O (T 
UJ 
2 0 
4 0 
eo 
8 0 
ao 
1 0 0 
(a) 
' ' . • . . * • ! ' ' 1 t • i « I 
0.01 0.1 10 1 0 0 
INHIBITOR CONCENTRATION big/mO 
Fig. 43. Inhibition of SLE autoantibodies binding by native and '02-02~-chromatin. 
Microtitre plates were coated with 'Oi-Or-chromatin (2.5ng/ml). (a) SLE sera 
5 and 6 by native chromatin (A,0) and 'Oa-Or-chromatin (A,«), (b) SLE sera 
7 and 8 by native chromatin (•,<>) and '02-0*2~-chromatin (• ,•) . 
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Fig. 44. Inhibition of SLE autoantibodies binding by native and '02-Or-chromatin. 
Microtitre plates were coated with 'Oa-Or-chromatin (2.5^g/nil). (a) SLE sera 
9 and 10 by native chromatin (A,0) and 'Oj-Or-chromatin (A,»), (b) SLE 
sera 11 and 12 by native chromatin (n,0) and 'Oi-Or-chromatin (•,•). 
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Fig. 45. Inhibition of SLE autoantibodies binding by native and 'Oz-Or-chromatin. 
Microtitre plates were coated with *02-02~-chromatin (2.5ng/ml). (a) SLE sera 
13 and 14 by native chromatin (A,0) and 'Oi-Or-chromatin (A.,«), (b) SLE 
sera 15 and 16 by native chromatin (D.O) and Oa-Or-chromatin (• ,•) . 
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Fig. 46. Inhibition of SLE autoantibodies binding by native and '02-Or-chromatin. 
Microtitre plates were coated with 'Oa-Or-chromatin (2.5 |ig/ml). (a) SLE sera 
17 and 18 by native chromatin (A,0) and 'Oa-Or-chromatin (A,«), (b) SLE 
sera 19 and 20 by native chromatin (D.O) and 'Oa-Or-chromatin (•,•) . 
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Fig. 47. Inhibition of SLE autoantibodies binding by native and 'Oi-Or-chromatin. 
Microtitre plates were coated with '02-02~-chromatin (2.5 ^g/ml). (a) SLE sera 
21 and 22 by native-chromatin (A,0) and '02-02~-chromatin (A.,«), (b) SLE 
sera 23 and 24 by native-chromatin (D.O) and '02-Or-chromatin (•,•) . 
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TABLE-7 
Inhibition of SLE autoantibodies binding to'Oj - 0*2-chromatin by 
native and 'Oj - OV-chromatin 
SLE Serum %J^JM^ li>^%^> ••SAM 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
Maximum percent inhibition at 20 ^g/ml 
Native chromatin 
24.0 
29.0 
30.0 
23.0 
31.0 
44.0 
24.0 
52.0 
25.0 
46.0 
23.0 
37.0 
35.0 
27.0 
20.0 
27.0 
40.0 
19.0 
20.5 
38.0 
8.0 
57.0 
21.0 
37.0 
'O2 - 02-chromatin 
42.0 
71.0 
55.0 
49.5 
46.0 
58.5 
43.5 
79.0 
38.5 
70.0 
53.0 
33.0 
58.0 
66.0 
53.0 
64.0 
65.0 
34.0 
30.0 
49.0 
10.0 
69.0 
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Fig. 48. Inhibition of SLE autoantibodies binding by native and 'OH-chromatin. 
Microtitre plates were coated with OH-chromatin (2.5 |j.g/nil). (a) SLE sera 1 
and 2 by native chromatin (A,0) and *OH-chromatin (A,«), (b) SLE sera 3 
and 4 by native chromatin (n,0) and 'OH-chromatin (• ,•) . 
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Fig. 49. Inhibition of SLE autoantibodies binding by native and *OH-chromatin. 
Microtitre plates were coated witli 'OH-chromatin (2.5 |ag/ml). (a) SLE sera 5 
and 6 by native chromatin (A,0) and 'OH-chromatin (A,»), (b) SLE sera 7 
and 8 by native chromatin (n.O) and 'OH-chromatin (• , •) . 
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Fig. 50. Inhibition of SLE autoantibodies binding by native and *OH-chromatin. 
Microtitre plates were coated with *OH-chromatin (2.5 ng/ml). (a) SLE sera 9 
and 10 by native chromatin (A,0) and 'OH-chromatin (A,*), (b) SLE sera 11 
and 12 by native chromatin (•,<>) and 'OH-chromatin (• ,•) . 
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Fig. 51. Inhibition of SLE autoantibodies binding by native and *OH-chromatin. 
Microtitre plates were coated with 'OH-chromatin (2.5ng/ml). (a) SLE sera 13 
and 14 by native chromatin (A,0) and 'OH-chromatin (A,#), (b) SLE sera 15 
and 16 by native chromatin (•,<>) and *OH-chromatin (• ,•) . 
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Fig. 52. Inhibition of SLE autoantibodies binding by native and *OH-chromatin. 
Microtitre plates were coated with 'OH-chromatin (2.5jag/ml). (a) SLE sera 17 
and 18 by native chromatin (A,0) and 'OH-chromatin (A,«) Q)) SLE sera 19 
and 20 by native chromatin (D.O) and *OH-chromatin (• , •) . 
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Fig. 53. Inhibition of SLE autoantibodies binding by native and 'OH-chromatin. 
Microtitre plates were coated with 'OH-chromatin (2.5|ag/ml). (a) SLE sera 21 
and 22 by native chromatin (A,0) and 'OH-chromatin (A,«) (b) SLE sera 23 
and 24 by native chromatin (•,<>) and 'OH-chromatin (• ,•) . 
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TABLE - 8 
Inhibition of SLE autoantibodies binding to *OH-chromatin by native 
and * OH-chromatin 
SLE Serum 
Maximum percent inhibition at 20 ^g/ml 
Native chromatin * OH -chromatin 
1 25.0 37.0 
2 33.0 79.0 
3 29.0 74.0 
4 21.0 58.0 
5 36.2 51.8 
6 25.0 22.4 
7 43.0 53.0 
8 61.0 81.0 
9 41.0 50.1 
10 49.3 69.0 
11 26.0 62.0 
12 26.0 49.0 
13 41.8 60.0 
14 27.8 46.0 
15 28.0 70.6 
16 43.0 50.0 
17 48.0 69.0 
18 19.6 39.0 
19 19.0 34.3 
20 29.0 47.0 
21 3.3 10.0 
22 51.0 63.0 
23 25.0 21.3 
24 33.0 45.0 
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Fig. 54. Elution profile of SLE IgG on Protein-A Sepharose CL-4B affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 55. Band shift assay of SLE IgG binding to (a) native-chromatin and (b) '02-02~-
chromatin. Antigen (2 ^g) was incubated with buffer (lane 1) and 20,40,60 
and 80 [ig of IgG through lanes 2 to 5, respectively for 2 hr at 37°C and 
overnight at 4°C. Electrophoresis was performed on 1% agarose gel for 2 hr. at 
30 mA. 
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Fig. 56. Band shift assay of SLE IgG binding to (a) native-chromatin and (b) 'OH-
chromatin. Antigen (2 jig) was incubated with buffer (lane 1) and 20,40,60 
and 80 ng of IgG through lanes 2 to 5, respectively for 2 hr at 37°C and 
overnight at 4°C. Electrophoresis was performed on 1% agarose gel for 2 hr. at 
30 mA. 
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Recognition of antibodies from cancer sera 
Sera from patients with various types of cancer were tested for binding to native 
and modified chromatin and the binding was evaluated using modified chromatin in 
competitive assay. The study comprised 22 sera from patients suffering from cancer of 
different organ and organ systems. Sera from normal healthy individuals served as 
control (Fig. 57). Cancer sera were obtained after careful clinical examination of patients 
with histopathological diagnosis attending J.N. Medical College Hospital, A.M.U.. 
Aligarh. 
Six sera were collected from patients with oral cancer. Out of these five sera 
showed higher reactivity with modified chromatin over native chromatin. Three sera 
showed a maximum inhibition of 73%, 54% and 65% with O2 - OVchromatin while two 
sera showed moderate inhibition (42% and 30%) (Fig. 58) with 'OH-chromatin 
inhibitions from 33% to 49% were obtained (Fig. 63). 
Four sera were collected from patients suffering from cancer of head and neck. 
Inhibitions ranging from 34 % to 72% were obtained in case of O2 - OVchromatin (Fig. 
59). With *OH-chromatin inhibitions ranging from 40% to 64% were obtained (Fig. 64). 
Four sera were collected from patients suffering from cancer of urinary bladder. 
Inhibitions of 65%, 52%, 47% and 39.4% were obtained with'Oi- d2'chromatin (Fig. 
60), and with *OH-chromatin all the four sera showed inhibitions of 70%, 56%, 52% and 
37% whereas with native chromatin all the three sera showed inhibition below 50% (Fig. 
65). 
Two sera from prostrate cancer and two from cancer of gall bladder were 
collected, maximum inhibitions of 47% and 51% were obtained with'Oa- oV-chromatin 
in case of prostrate cancer, sera from cancer of gall bladder showed inhibitions of 49% 
and 43% with'Oa- Olrchromatin, with native chromatin inhibitions ranging from 35% to 
42% were obtained (Fig. 61). With OH-chromatin, sera from cancer of prostrate showed 
inhibitions of 57% and 54%, while sera from cancer of gall bladder showed inhibitions of 
63% and 57%. With native chromatin inhibitions of 38% to 43% were obtained (Fig. 66). 
One serum sample each from breast cancer and lung cancer were tested for native 
and modified chromatin. Serum from breast cancer showed inhibition of 59% with O2 -
d2-chromatin and 51% with *OH-chromatin. Serum of lung cancer showed moderate 
inhibition of 29% with'Oa- O'z'-chromatin and inhibition of 35% with 'OH-chromatin. 
One serum sample from patient suffering from CML showed a moderate inhibition of 
29% with 'O2 - OV-chromatin and somewhat higher inhibition of 49% with 'OH-
chromatin. One serum sample from patients suffering from Hodgkin's lymphoma showed 
an inhibition of 47% with 'O2 - oVchromatin while a higher recognition i.e. 77% 
inhibition with *0H chromatin (Figs. 62,67). 
The binding data of cancer sera with native and modified chromatin are shown in 
Tables 9 and 10. 
Purification of cancer IgG 
Cancer IgG was purified by affinity chromatography on Protein-A sepharose Cl-
4B column (Fig. 68), Purified IgG migrated as a single homogenous band on SDS-PAGE 
under non-reducing conditions (Fig. 68, inset). 
Band shift assay 
The binding of native and modified chromatin to cancer IgG was detected by 
band shift assay. Constant amounts of antigens were incubated with varying amounts of 
cancer IgG for 2 hrs at room temperature and overnight at 4°C. Immune complexes were 
electrophoresed on 1% agarose of 2 hr at 30 mA. Figure 69 shows the binding of cancer 
IgG to native chromatin and O2 - OVchromatin and Figure 70 shows the binding of 
cancer IgG to native chromatin and 'OH-chromatin. With increasing concentrations of 
IgG there is corresponding increase in the formation of high molecular weight immune 
complexes as reflected by the retarded mobility and corresponding decrease in the 
fluorescence intensity of unbound antigen. 
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Fig. 57. Binding of various cancer sera to native ( ^ ) , 'Oa-Or-chromatin (BV), and 
'OH-chromatin ( H ) , nonnal human sera (NHS) served as negative control. 
The histograms show mean absorbance values for binding of NHS and sera 
from patients with oral cancer (1), cancer of head and neck (2), urinary bladder 
(3), gall bladder (4), prostrate (5), breast (6), lung (7), CML (8), Hodgkin's 
lymphoma (9). 
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Fig. 58. Detection of autoantibodies against native and '02-02~-chromatin in the sera 
of patients with oral cancer, (a) Cancer sera 1,2 and 3 by native-chromatin 
(A,0,n), and '02-02~-chromatin (A,0,1), (b) Cancer sera 4,5 and 6 by native-
chromatin (A,0,n) and *02-02~-chromatin (A,0,B). The microtitre plates were 
coated with *02-02~-chromatin (2.5 ^ g/ml). 
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Fig. 59. Detection of autoantibodies against native and 'Oi-Or-chromatin in the sera 
of patients with cancer of head and neck, (a) Cancer sera 1 and 2 by native-
chromatin (A,o), and 'Oa-Or-chromatin (A,0), (b) Cancer sera 3 and 4 by 
native-chromatin (D,0) and 'Oz-Or-chromatin (•,•) . The microtitre plates 
were coated with 'Oa-Or-chromatin (2.5 i^g/ml). 
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Fig. 60. Detection of autoantibodies against native and '02-02~-chromatin in the sera 
of patients with cancer of urinary bladder, (a) Cancer sera 1 and 2 by native-
chromatin (A,0), and 'Oi-Or-chromatin (A,0), (b) Cancer sera 3 and 4 by 
native-chromatin (D,0) and 'Oa-Or-chromatin (• ,•) . The microtitre plates 
were coated with 'Oi-Or-chromatin (2.5 |ig/ml). 
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Fig. 61. Detection of autoantibodies against native and 'Oi-Or-chromatin in the sera 
of patients with cancer of (a) Gai| bladder, sera 1 and 2 by native-chromatin 
(A,0), and '02-Or-chromatin (A,0), (b) Prostrate, sera 1 and 2 by native-
chromatin (D.O) and 'Oz-Or-chromatin (•,•) . The microtitre plates were 
coated with 'Oi-Or-chromatin (2.5 jig/ml). 
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Fig. 62. Detection of autoantibodies against native and '02-02~-chromatin in the sera 
of patients with cancer of (a) Breast and lung by native-chromatin (A,0), and 
'02-Or-chromatin (A,o), (b) CML and Hodgkin's lymphoma by native-
chromatin (n,0) and 'Oi-Or-chromatin (•,•). The microtitre plates were 
coated with 'Oj-Or-chromatin (2.5 i^g/ml). 
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TABLE- 9 
Inhibition of binding of antibodies in cancer sera to^ Oj - 02-chromatin 
by native and 'o^ - oVchromatin 
Maximum percent inhibition at 20 (xg/ml 
Type of Cancer No. of sera tested 
Native Chromatin O2 - 02-chromatin 
Oral Cancer 6 48.0 37.0 
39.0 73.0 
43.0 54.0 
33.7 41.8 
30.0 65.0 
26.0 28.0 
Head and Neck 4 50.1 72.0 
40.0 49.9 
17.3 38.0 
18.0 34.0 
Urinary Bladder 4 39.0 52.0 
47.0 65.0 
19.0 47.0 
31.9 39.4 
Gall Bladder 2 39.0 49.0 
36.0 43.0 
Prostrate 2 42.0 47.0 
35.0 51.0 
Breast 1 48.0 59.0 
Lung 1 15.0 29.0 
CML 1 20.0 29.0 
Hodgkin's 1 21.0 47.0 
lymphoma 
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Fig. 63. Detection of autoantibodies against native and 'OH-chromatin in the sera of 
patients with oral cancer, (a) Cancer sera 1, 2 and 3 by native-chromatin 
(A.O.D), and 'OH-chromatin (A.O.l), (b) Cancer sera 4, 5 and 6 by native -
chromatin (A.O.D) and 'OH-chromatin (A.O.B). The microtitre plates were 
coated with 'OH-chromatin (2.5 i^g/ml). 
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Fig. 64. Detection of autoantibodies against native and 'OH-chroraatin in the sera of 
patients with cancer of head and neck, (a) Cancer sera 1 and 2 by native-
chromatin (A,0), and *OH-chromatin (A,t), (b) Cancer sera 3 and 4 by native 
-chromatin (D.O) and *OH-chromatin (•,•) . The microtitre plates were 
coated with 'OH-chromatin (2.5 ^ ig/ml). 
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Fig. 65. Detection of autoantibodies against native and 'OH-chromatin in the sera of 
patients with cancer of urinary bladder, (a) Cancer sera 1 and 2 by native-
chromatin (A,0), and 'OH-chromatin (A,0), (b) Cancer sera 3 and 4 by native 
-chromatin (•,<>) and 'OH-chromatin(l,4). The microtitre plates were coated 
with *OH-chromatin (2.5 i^g/ml). 
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Fig. 66. Detection of autoantibodies against native and 'OH-chromatin in the sera of 
patients with cancer of (a) Gall bladder, sera 1 and 2 by native-chromatin 
(A,0), and *OH-chromatin(A,o), (b) Prostrate, sera 1 and 2 by native-
chromatin (n,0) and *OH-cliromatin(B». The microtitre plates were coated 
with *OH-chromatin (2.5 |ig/ml). 
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Fig. 67. Detection of autoantibodies against native and *OH-chromatin, in the sera of 
patients with cancer of (a) Breast and lung by native-chromatin (A,0), and 
*OH-chromatin (A,o). (b) CML and Hodgkin's lymphoma by native-
chromatin (n,0) and *OH-chromatin (•,•). The microtitre plates were coated 
with *OH-chromatin (2.5 i^g/ml). 
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TABLE -10 
Inhibition of binding of antibodies in cancer sera to *OH-chromatin by 
native and * OH-chromatin 
Type of Cancer 
Oral Cancer 
Head and Neck 
Urinary Bladder 
Gall Bladder 
Prostrate 
Breast 
Lung 
CML 
Hodgkin's 
lymphoma 
No. of sera tested 
6 
4 
4 
2 
2 
1 
1 
1 
1 
Maximum percent 
Native chromatin 
50.0 
32.0 
40.0 
30.0 
24.0 
27.0 
43.0 
37.0 
22.0 
18.0 
41.0 
45.0 
19.0 
25.0 
40.0 
38.5 
43.0 
38.3 
45.0 
12.0 
20.0 
25.0 
inhibition at 20 ^g/ml 
*OH-chromatin 
49.0 
45.0 
49.0 
43.0 
38.0 
33.0 
58.4 
48.0 
39.5 
64.0 
55.8 
69.6 
52.0 
37.0 
63.0 
57.0 
56.9 
54.3 
51.0 
35.0 
49.0 
77.0 
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Fig. 68. Elution profile of cancer IgG on Protein-A Sepharose CL-4B affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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(a) 
Fig. 69. Band shift assay of cancer IgG binding to (a) native-chromatin and (b) ' O2-
02"-chromatin. Native-chromatin (l|ig) and '02-02"-chromatin (l|ag) were 
incubated with 10, 20, 40 and 80 i^g of IgG for 2 hr at 37°C and overnight at 
4°C. Electrophoresis was carried out on 1% agarose gel for 2 hr at 30 mA. 
Lane 1 contains native or '02-02~-chromatin, while lanes 2,3,4, and 5 contain 
native or '02-02'-chromatin with increasing concentrations of cancer IgG. 
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Fig. 70. Band shift assay of cancer IgG binding to (a) native-chromatin and (b) 'OH-
chromatin. Native-chromatin (1 |ig) and *OH-chromatin (1 |ag) were incubated 
with 10,20,40 and 80 |ag of IgG for 2 hr at 37°C and overnight at 4°C. 
Electrophoresis was carried out on 1% agarose gel for 2 hr. at 30 mA. Lane 1 
contains native or 'OH-chromatin, while lanes 2, 3, 4, and 5 contain native or 
'OH-chromatin with increasing concentrations of cancer IgG. 
f&ou^kHo^^ 
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Reactive oxygen species such as hydroxyi radical, superoxide anion radical, 
hydrogen peroxide and singlet oxygen are continuously produced during normal cellular 
metabolism. It is now well established that free radicals and other reactive oxygen species 
are continuously produced in vivo, and can damage most cellular components (Martinez-
Caynela, 1995). These radicals modify DNA at various sites that include base damage 
(Dizdaroglu et al., 1991) leading to mutations (Moody and Hassan, 1982; Brawn and 
Fridovich, 1985), may activate proto-oncogenes and act as promoters of carcinogenesis 
(Cerutti, 1985; Crawford et al, 1988; Clayson et al, 1994; Ames et al, 1995). 
Oxygen derived species such as superoxide (OD, H2O2, singlet oxygen ('O2) and 
hydroxyi radical ('OH) are well known to be cytotoxic and have been implicated in the 
etiology of a number of human diseases including SLE and cancer (Cerutti, 1985; 
Halliwell and Gutteridge, 1989; 1990; Lunec, 1990; Blount et al, 1994; Cooke et al, 
1997). Amongst ROS, the hydroxyi radical is an extremely reactive oxidizing radical, 
formed in vivo via ionizing radiations (Breen and Murphy, 1995) or through Haber Weiss 
or Fenton reactions (Aruoma et al, 1991). These radicals interact indiscriminately with 
all components of the DNA molecule causing DNA damage which includes 
modifications of all the four nitrogenous bases leading to mutations, single and double 
strand breaks and apurinic sites (Halliwell and Aruoma, 1991). Hydroxyi radicals are also 
believed to be responsible for a major part of the chromatin damage (Brawn and 
Fridovich, 1981; Halliwell, 1987;Nassi-Coloera/., 1989; Friedberg era/., 1995). 
Superoxide is the most abundant reactive species generated in vivo by several 
enzymatic and non-enzymatic pathways in mammalian tissue (Fridovich, 1986; 
Devasagayam et al, 1991; Sies and Menck, 1992). The superoxide anion radical (OD is 
considered to be a highly toxic entity in many biological systems (von Sonntago, 1987). 
Superoxide anion radical is capable of damaging chromosomal DNA (Emerit, 1986). 
Chromosomal breakage was observed in several autoimmune diseases, such as lupus 
erythematosus, rheumatoid arthritis, ulcerative colitis (Emerit, 1986). Similarly 
chromosomal abnormalities have also been described in some multiple sclerosis patients 
(Emerit and Marteau, 1971). Therefore it is possible that superoxide radical produced in 
excessive amoimts might be responsible for DNA damage in autoiimnune diseases. 
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Singlet oxygen ('O2) is a potent biological toxin. It oxidatively damages a variety 
of biological molecules including DNA (Foote, 1981; Straight and Spikes, 1985; Wefers 
et al., 1987) and kills both bacteria and mammalian cells (Dahl, 1987; 1991). Because of 
its action at the DNA base level and may be on the sugar phosphate backbone, singlet 
oxygen should be considered as a DNA damaging agent when generated in the DNA 
vicinity. There are several lines of evidence supporting the idea that singlet oxygen is one 
of the major cytotoxic species to eukaryotic cells (Dubbelman et al., 1988), bacteria (Epe 
et al., 1989) and viruses (Houba-Herin et al., 1982). ft has been demonstrated that 'O2 
reacts preferentially with guanine residues either as free nucleosides (Cadet et al., 1983) 
or as components of the DNA molecule (Menck et al., 1993) yielding a variety of DNA 
lesions selectively at giumine sites. 
Human exposure to reactive oxygen species has been implicated in the etiology of 
a number of autoimmune diseases including SLE. An important role of oxidative DNA 
damage has also been suggested in autoimmune diseases such as SLE. (Halliwell and 
Gutteridge, 1989; Bashir et a/., 1993). SLE is a systemic autoimmune disorder 
characterized by a marked diversity of organ involvement and fluctuations in disease 
activity (Min et al, 2002). Although the pathogenesis process of SLE has not yet been 
clearly established, several autoantibodies have been implicated in its pathogenesis and in 
tissue damage (Koffler, 1974; Tan et al., 1988). Antibodies to DNA in SLE have been 
extensively studied and may be specific for ssDNA, reactive with both ssDNA and 
dsDNA, or specific for dsDNA (Stollar, 1979; Worral et al, 1990). Anti-dsDNA 
antibodies are strongly co-related with diagnosis of SLE (Tan, 1989) Serum antibodies 
reacting with chromatin or its predominant components, histones and DNA, have been 
found in SLE, drug induced lupus, several other human disease states and in murine 
models of SLE (Schwartz and Stollar, 1985; Burlingame and Rubin, 1991; 
Theofilopoulos and Dixon, 1985; Portanova et al, 1988; Costa and Monier, 1986; Fisher 
et al, 1988). Chromatin is an immunogenic stimulus for B cells in SLE, and anti-native 
DNA antibodies are a subset of the wide range of anti-chromatin antibodies produced in 
this disease (Burlingame et al., 1994). Studies have demonstrated that, since SLE patients 
may suffer from an increased rate of oxidative damage and also a deficient repair 
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mechanism, they are at an increased risk of malignant diseases (Bashir et al., 1993; Lunec 
etal., 1994). 
Cancer has been implicated in free radical induced damage to DNA (Ames et al., 
1993a; 1995). Reactive oxygen species produced exogenously and endogenously are 
known to play an important role in the initiation and promotion of multistage 
carcinogenesis (Totter, 1980; Ames, 1989; Toyokuni et al., 1994; Sadani and Nadkarni, 
1996; Pryor, 1997) 
In the present study chromatin was isolated from goat liver. Isolated chromatin 
exhibited major peak at 260 nm and negligible absorbance at around 320 nm, A25g/A28() 
ration was 1.63 and A258/A320 ratio was around 9. It migrated as a single homogenous 
electrophoretic band on 1% agarose gel. 
Isolated chromatin was modified by superoxide anion radical and singlet oxygen 
('02-Or) generated by illumination of riboflavin at 365 nm and hydroxyl radical ('OH) 
generated by irradiation of hydrogen peroxide and 254 nm UV light. The present study 
shows that the damage observed by illumination of riboflavin system in a metal free 
solution is due to the production of singlet oxygen ('O2) and superoxide anion radical 
(02~). The production of these radicals was confirmed by the use of quenchers, sodium 
azide and superoxide dismutase (SOD) for singlet oxygen and superoxide radical 
respectively. Nearly complete inhibition in the production of 'O2 was observed in 
presence of 100 mM sodium azide. No inhibition in the production of O r was observed 
when SOD alone was used. However inhibition in the production of O r was observed 
when both SOD and sodium azide were used. This could be due to the reason that when 
SOD is exposed to a singlet generating system it becomes susceptible to oxidative 
modification and damage as indicated by the loss of activity (Kim, et al., 2001) and hence 
SOD alone could not inhibit the production of 02~ but when sodium azide was also 
introduced in the system at a concentration at which almost complete inhibition of 'O2 
production was observed, SOD was not inactivated and inhibition in the production of 
o r was observed. 
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Production of *0H was confimied using mannitol as the quencher of 'OH. 
Inhibition in the production of *0H was observed when mannitol was added to the 
system generating *0H. 
The UV absorption spectra of 'Oa-Or-chromatin showed hyperchromicity at 260 
nm at a peak shift of 12 nm towards longer wavelength. This could be attributed to single 
strand breaks and modification of bases in DNA of chromatin. The UV difference 
spectral curve exhibited increased absorbance at 275 nm and a shoulder at 282 nm. These 
are indicative for an appreciable proportion of superoxide and singlet oxygen induced 
damage of bases and disruption of chromatin structural organisation. UV absorption 
spectra of '02-02~-chromatin in presence of sodium azidc shows that the damage 
obtained in the presence of quencher of 'Oj may be due to the production of O2 only. 
UV absorption spectra of *OH-modified chromatin shows decrease in absorbance 
at 260 nm. UV difference spectral curve of "Oll-chromatin with reference to native 
chromatin shows a negative peak between 260 to 270 nm indicating hypochromicity of 
modified chromatin. This could be due to the damage of chromophoric groups, 
modification of bases in DNA of chromatin or due to structural alteration of chromatin. 
UV absorption spectra of 'OH-chromatin in presence of mannitol, a specific quencher of 
'OH radicals shows less damage confirming that the damage is due to the production of 
'OH radicals. 
Formation of single stranded regions in modified chromatin was studied by 
nuclease SI digestibility of native and modified chromatin. When native and O2-O2 -
chromatin were subjected to nuclease SI digestion, a substantial decreased intensity in 
case of modified sample was found however the intensity loss in case of native chromatin 
shows that some of the single stranded regions are present in unmodified sample also but 
intensity loss was more in case of modified sample showing the formation of single 
stranded regions on exposure to 'O2 and 02~. Similar results were obtained with 'OH-
modified chromatin. 
The thermal denaturation profile of native and 'O2-O2 -chromatin showed a net 
decrease of 6°C in the Tm value for modified chromatin as compared to its unmodified 
native form. Similarly thermal denaturation profile of native and 'OH-chromatin showed 
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a net decrease of 9°C in the Tm value. This could be attributed to disruption of hydrogen 
bonding pattern, generation of single strand regions or due to structural alterations of 
chromatin on exposure to 'O2, Or or *0H. 
Native DNA per se is known to be a poor immunogen (Madaio et al., 1984; 
StoUar, 1986), whereas double stranded RNA, RNA-DNA hybrids, double helical 
polydeoxyribonucleotides, ribohomopolymers, poly(G), poly(I), poly(U), DNA modified 
with drugs, hormones, chromatin or DNA in complexes with DNA binding proteins 
induce antibodies (StoUar, 1973; 1975; 1986; Anderson et al., 1988a; Desai et al, 1993; 
Moinuddin and Ali, 1994; Arjumand et al., 1995; Hasan et al., 1995; Theofilopoulos, 
1995; Arif and Ali, 1996; Arjumand et al., 1997). 
Chromatin itself is immunogenic. But in diseases like SLE it becomes more 
immunogenic. This might be due to the exposure of chromatin to reactive oxygen 
species, altering the structure of chromatin and rendering it more immunogenic. It has 
been suggested previously that the change of chromatin's antigenicity by environmental 
factors and genetic background maybe the common pathway to SLE pathogenesis (Lu et 
al., 1998). 
Both native and modified chromatin were found to be immunogenic in rabbits as 
revealed by direct binding and inhibition ELISA results. But 'Oi-Or-chromatin and 
'OH-chromatin were found to be highly immunogenic as compared to immodified native 
chromatin. Band shift assays clearly demonstrated the absolute specificity of the purified 
immune IgG towards their respective immunogen. Antigenic specificity of purified IgG 
was confirmed by inhibition ELISA. A maximum of 68% inhibition of anti-native 
chromatin antibody with immunogen as inhibitor was observed at 20 |ig/ml and 50% 
inhibition was achieved at 14.7 ng/ml. A maximum of 75% inhibition in the binding of 
anti-'02-Or-chromatin antibody with immunogen as inhibitor was observed at 20 ^g/ml 
and 50% inhibition was achieved at 13.3 ng/ml. A maximum of 85% inhibition in the 
binding of anti-'OH-chromatin antibody with immunogen as an inhibitor at 20 ng/ml was 
observed and 11.8 ng/ml of immunogen was required for 50% inhibition. The data shows 
that although native chromatin was found to be immunogenic in experimental animals but 
chromatin modified with oxygen firee radicals was found to be highly immimogenic. This 
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could be correlated to a feature SLE wherein reactive oxygen species modified chromatin 
or DNA play major role in the production of SLE autoantibodies by the modification of 
DNA (or nucleosomes) thus forming neoantigen(s) resulting in the production of 
autoantibodies. 
Autoantibodies targeted against intracellular proteins and nucleic acids are the 
serological hallmark of the systemic rheumatic diseases, such as systemic lupus 
erythematosus (SLE), progressive systemic sclerosis (PSS), Sjogren's syndrome (SS). 
mixed connective tissue disease (MCTD) and polymyositis (PM). Each of these diseases 
are identified by unique autoantibodies. Antibodies to dsDNA serve as an 
immimochemical marker for the diagnosis of SLE. It has been shown that DNA after 
exposure to ROS presents a more discriminating antigen for the binding of SLE 
autoantibodies (Blount et ai, 1989; 1990; Ara and AH, 1992; 1993; Cooke et al., 1997). 
Several studies have reinforced the concept that SLE is an anti-chromatin disease 
e.g., that the autoimmune response is against chromatin with the development of 
antibodies directed to various epitopes on chromatin including but not limited to DNA 
(Burlingame et ai, 1993; 1994; Amoura et ai, 1994; Mohan et ai, 1993; Tax el al., 
1995; Chabre et al., 1995). In the present study, autoantibodies from twenty-four 
different SLE sera were screened by direct binding and inhibition ELISA. All sera except 
two showed considerable binding to native and modified chromatin. No detectable 
antibody activity was found in normal human sera. 
Competition ELISA results showed 8% to 61% inhibition in the SLE 
autoantibodies binding to native chromatin, whereas, 30% to 76% was observed with 
'02-Or-chromatin as competitor. Similarly 23% to 81% inhibition was observed with 
*OH-chromatin as inhibitor. These results indicate that the modified chromatin is an 
effective inhibitor showing substantial difference in the recognition of '02-02~-chromatin 
and *OH-chromatin over native chromatin. Band shift assay further substantiated the 
binding of native and modified chromatin with SLE autoantibodies. 
Increased levels of circulating antibodies and autoantibodies have been reported 
in sera of patients with cancer (Tannenberg et al., 1973; Whitehouse, 1973; Wasserman 
et al., 1975; Anderson et al., 1988b; Chagnaud et al., 1992; Faiderbe et al., 1992; Becker 
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et al, 1994). Elevated levels of anti-nuclear antibodies upto 27% in cancer have been 
reported (Bunham, 1972; Zeronski et al, 1972). In the present study, the presence of 
autoantibodies reactive towards native and modified chromatin in sera of patients with 
cancer was also studied. The study comprised of twenty two sera from patients with 
various types of malignancies. 
Six sera from oral cancer showed higher recognition to modified chromatin as 
compared to native chromatin. Similarly four sera of patients with cancer of head and 
neck showed preference to '02-02~-chromatin over "OH-chromatin as compared to native 
chromatin. Results obtained with sera from cancer with urinary bladder, gall bladder and 
prostate showed higher recognition to modified chromatin as compared to native. One 
serum sample each from patients of cancer of breast, lung, CML and Hodgkin's 
lymphoma showed greater recognition to modified chromatin over native chromatin. 
Further the binding of native and modified chromatin with circulating cancer 
autoantibodies was substantiated by gel retardation assay. These results are indicative of 
the presence of reactive oxygen species induced DNA damage in cancer patients. 
Presence of autoantibodies in cancer sera reactive towards modified and native chromatin 
may be attributed to '02-0r and 'OH induced damage to chromatin rendering it 
immunogenic. The autoantibodies may, therefore, be raised primarily against modified 
chromatin and cross react with native chromatin. Earlier studies have shown that 
endogenous levels of typical free radical modified pyrimidines and purines of DNA in 
chromatin samples isolated from various human cancerous tissues were found to be 
consistently higher than in their respective cancer free surrounding tissues (Olinski et al.. 
1992). 
Based on the above studies, the following conclusions can be drawn: 
1. Illumination of chromatin in presence of riboflavin resulted in the generation of 
singlet oxygen and superoxide anion radical, which resulted in the formation of 
single strand breaks and base modifications in DNA of chromatin. 
2. Chromatin irradiated at 254 nm UV light in the presence of hydrogen peroxide 
resulted in the generation of hydroxyl radical, which damaged chromatin. 
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resulting in the formation of strand breaks and modifications of DNA bases in 
chromatin. 
3. '02-02~-chromatin and *OH-chromatin were highly immimogenic in experimental 
animals as compared to native-chromatin. 
4. Induced antibodies were highly specific for respective immunogens. 
5. SLE autoantibodies showed preferential binding to '02-02~-chromatin and *0H-
chromatin over native chromatin. 
6. 'O2-O2 -chromatin and 'OH-chromatin present a discriminating antigen for the 
binding of SLE autoantibodies. 
7. Antibodies in the sera of various cancer patients recognized '02-Or-chromatin 
and *OH-chromatin to great extent as compared to native-chromatin. 
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